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Abstract 
Ora A. Weisz, PhD 
 
Tubular Proteinuria and Vitamin D Deficiency in Sickle Cell Disease 
Megan Laura Gliozzi, PhD 
University of Pittsburgh, 2019 
 
Abstract 
Kidney disease is a significant complication of sickle cell disease (SCD) with great public 
health concern, causing over 18% of total patient mortality. Proximal tubule (PT) dysfunction, 
including tubular proteinuria, is a common early symptom of kidney disease in SCD patients and 
can lead to chronic kidney disease. Although not well understood, PT dysfunction in SCD is 
thought to be caused by exposure to higher cell-free hemoglobin (Hb) concentrations from 
increased red blood cell hemolysis. Hb is filtered by the glomerulus to enter the tubule lumen, 
where it is reabsorbed by PT cells upon binding to multiligand receptors megalin and cubilin. 
Megalin and cubilin bind to numerous proteins in the kidney filtrate, including albumin, vitamin 
D binding protein (DBP), and retinol binding protein (RBP), and are important for maintaining 
vitamin homeostasis and a protein-free urine. 
To better understand PT dysfunction at the cellular level, we treated PT cells with 
physiologic levels of Hb estimated in SCD and measured protein endocytosis and 
toxicity/oxidative stress. We found that Hb inhibited albumin, DBP, and RBP uptake by PT cells 
to variable degrees. Hb inhibition occurred in the absence of a cytotoxic response and appeared to 
be due to direct competition for megalin/cubilin binding. These results suggest that binding 
competition between Hb and normally filtered proteins may be the primary cause of tubular 
proteinuria in SCD patients. Additionally, Hb inhibition appeared to be selective for highly alpha 
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helical proteins. Understanding the selectivity of Hb binding competition could help to identify 
biomarkers and therapeutic compounds to detect and treat tubular proteinuria in SCD patients prior 
to the onset of kidney disease. 
Inhibition of DBP uptake by PT cells could contribute to vitamin D deficiency commonly 
observed in SCD patients. We also found prolonged Hb exposure created an increased cytotoxic 
response and alteration of vitamin D hydroxylase expression in PT cells, indicating Hb-induced 
toxicity may affect vitamin D metabolism.  Finally, we observed selective changes in protein 
reabsorption by PT cells with variation of active vitamin D availability, suggesting further possible 
complications in protein reabsorption and vitamin D homeostasis in SCD patients with low vitamin 
D status.  
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1.0 Introduction 
1.1 Public Health Significance 
Sickle cell disease (SCD) is the most common hereditary hemoglobinopathy and one of 
the most common monogenic diseases, affecting approximately 300,000 newborns annually [1, 2] 
and 100,000 individuals in the United States [3]. The number of individuals affected by SCD in 
the United States is predicted to rise as advances in medicine and patient treatment have led to a 
drastic increase in SCD patient lifespan. Over the past 40 years alone the median SCD patient life 
expectancy has risen from 14.3 years (1970s) to 61 years (2014) [4, 5]. Unfortunately, as patients 
are living longer, they are developing more severe secondary organ damage that is proving to 
require an entirely new therapeutic approach.  
One of the most common and severe secondary complications of SCD is sickle cell 
nephropathy (SCN). In fact, kidney-related injury and disease account for 16-18% of total SCD 
patient mortality and renal failure ranks within the top three most common primary causes of death 
in patients [6-8]. The prevalence of SCN is also predicted to rise in the coming years due to 
disproportionate advances in treatment of SCD and SCN. Diagnosis, prevention, and treatment of 
early kidney disease are lacking and kidney injury in patients can quickly progress to chronic 
kidney disease (CKD), in which the median age of onset is 37 years old [9]. CKD is present in 
approximately 11.6% of SCD patients, making it the most common SCN manifestation [9]. 
Unfortunately, treatment options once a patient progresses into CKD and/or renal failure are 
limited to renal replacement therapy. Thus, there is an immense need for improved kidney-specific 
treatment and prevention of kidney disease progression in SCD patients. 
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Symptoms of SCN can manifest as early as infancy in SCD patients. One of the earliest 
observed SCN symptoms in patients is development of tubular proteinuria, indicating dysfunction 
of the proximal tubule (PT) segment of the nephron [10-12]. While PT dysfunction and tubular 
proteinuria have not yet been linked to progression of kidney disease in SCN, both have been 
linked to kidney inflammation and fibrosis in other diseases and can eventually lead to glomerular 
dysfunction, frank proteinuria, and end-stage renal failure (ESRD) [13, 14].  
Additionally, PT dysfunction can prevent normal uptake of several vitamin carriers that 
bind to megalin and cubilin, including vitamin D binding protein (DBP) and retinol binding protein 
(RBP) [15]. Failure to reabsorb these carrier proteins can lead to vitamin deficiencies. This is 
particularly true for vitamin D as the PT is the primary site for vitamin D reclamation and 
activation [16]. There is a high prevalence of vitamin D deficiency in SCD patients [17, 18], which 
may be due in part to PT dysfunction. Additionally, vitamin D deficiency is reportedly correlated 
with increased inflammation and vaso-occlusive crises in SCD patients [19]. Together, this 
suggests early PT dysfunction could hinder the critical maintenance of vitamin D status in SCD 
patients to further contribute to disease pathogenesis.  
1.2 Sickle Cell Disease 
SCD was first characterized in 1910 upon the observation of “sickle-shaped” red blood 
cells (RBCs) in a blood sample [20]. It is most prevalent in areas plagued by malaria due to the 
protective effect of the sickle cell trait against infection. However, the distribution of SCD has 
spread outside these areas due to global migration in the last two centuries [21, 22]. SCD is caused 
by mutation of the hemoglobin β-globin subunit gene, HBB. While many disease-causing variants 
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have been reported, the classic and most well-studied variant, hemoglobin S (HbS), is caused by a 
single nucleic acid change (c.17T>A), leading to an amino acid change (p.Glu6Val) early in the 
β-globin protein. The HbS mutation changes the structural integrity of hemoglobin (Hb) to 
promote polymerization in RBCs, forcing the affected cells into a rigid, sickled shape that 
increases the likelihood of vasculature blockage and RBC hemolysis.  
1.2.1  Sickle cell disease genetics 
The most prevalent form of SCD is sickle cell anemia, which is caused by the inheritance 
of two HbS variants [23]. Although all reported SCD genotypes contain at least one copy of the 
HbS variant, many other pathogenic HBB variants exist. Other variants include different single 
and dual point mutations and large deletions within the HBB gene. Appendix A Table 2, modified 
from reference [1], provides a comprehensive list of genotypes previously reported to cause SCD 
characterized by their associated disease severity. 
Most SCD cases outside of sickle cell anemia are caused by hemoglobin SC disease, which 
is characterized by the coinheritance of the HbS and hemoglobin C (HbC) variants [24]. The third 
most common form of SCD occurs through coinheritance of the HbS variant and β-thalassemia 
alleles [1]. Rather than altering Hb’s structural conformation, β-thalassemia alleles decrease 
production of the affected HBB gene and are characterized by the reduction in protein expression 
(for more information on β-thalassemia see reference [25]). All other SCD cases caused by various 
mutations are quite rare and thus not well studied. 
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1.2.2  Hemoglobin 
Expressed exclusively in RBCs (immature reticulocytes and mature erythrocytes), Hb is 
the primary circulating oxygen carrier protein in the body. Within RBCs, Hb functions as a 
heterotetramer comprised of two symmetric heterodimer pairs and one heme molecule per 
monomer [26]. Hb dimers are created by the association of one polypeptide chain from the α-
globin gene cluster (α and ζ genes; chromosome 16) and another from the β-globin gene cluster 
(β, γ, ε genes; chromosome 11) [27]. These gene clusters have evolved to create a temporal 
expression pattern throughout development, shifting gene expression from 5’ to 3’ during the 
progression from fetus to adult (Fig. 1) [27, 28].  
The most commonly expressed Hb formation in adults is hemoglobin A (HbA), which 
consists of two αβ heterodimers [26, 27]. However, the principally expressed Hb formation in fetal 
development is hemoglobin F (HbF), comprised of two αγ heterodimers. HbF is expressed during 
fetal development to facilitate oxygen flow from mother to fetus as it has a stronger affinity for 
oxygen than HbA [27]. After birth, γ-globin genes are downregulated and the β-globin gene is 
upregulated (Fig. 1), shifting Hb tetramer expression from HbF to HbA within the first year of life 
[29]. Because of this shift in expression after birth, SCD patients are commonly asymptomatic 
until around 8-10 weeks of age [30]. Although significant progress has been made recently to 
elucidate the regulation of the expressional shift from γ-globin to β-globin [31], the exact 
mechanism is still not completely understood.  
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Figure 1. Globin gene location and temporal expression during development. 
Hb monomer globin gene clusters are spatially arranged on chromosomes (α-like on Chr.16 and β-like on Chr.11) 5’ 
to 3’ (A) to mirror expression changes during development and adulthood (B). ζ-globin and ε-globin genes are first 
expressed in the fetal yolk sac, para-aortic region, and liver. Around six weeks after conception, these genes are 
downregulated and the α-globin (α1 and α2) and γ-globin (Aγ and Gγ) genes are upregulated, giving rise to a 
predominant hemoglobin F (HbF) expression.  Downregulation of γ-globin genes and upregulation of β-globin begins 
at birth [27]. At approximately 8-10 weeks postnatal, the majority of Hb tetramers are hemoglobin A (HbA) type [30]. 
 
Adult Hb αβ tetramers are spatially arranged so that α-globin monomers bind to β-globin 
monomers via two distinct interfaces with differing binding affinities, denoted as α1β1 and α1β2. 
Initially, αβ dimers form through extremely high affinity binding at the α1β1 interface. These 
dimers then interact with each other through a lower affinity α1β2 interface, forming tetramers [32]. 
The α1β2 interface is destabilized upon oxygen molecule (O2) binding at the heme group of one 
subunit to create a conformational change within the tetramer, facilitating additional O2 binding at 
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other heme sites. This cooperative binding of O2 is considered positive allosteric regulation as each 
bound O2 enhances O2 binding at other sites within the tetramer [32]. Alternatively, allosteric 
regulation of O2 binding by other molecules can promote O2 release when tissue oxygenation is 
needed. For example, metabolic tissues with high O2 demands produce large amounts of carbon 
dioxide (CO2) which is taken up and metabolized by erythrocytes, producing carbonic acid and 
one hydrogen atom (H+) per reaction. H+ allosterically interacts with Hb, a process referred to as 
the Bohr effect, to stimulate O2 release and delivery to the tissue [33]. Additionally, 2,3-
diphosphoglycerate (2,3-DPG), a by-product of glycolysis, can allosterically regulate Hb to 
facilitate O2 release, ensuring efficient O2 delivery to metabolically active tissues [34].  
In order to bind O2, the iron within the heme group of each subunit must be in its reduced 
ferrous (Fe2+) state. This form of Hb is referred to as oxyhemoglobin (oxyHb) and is the primary 
circulating form of Hb. Because O2 has a higher redox potential than iron, oxyHb can occasionally 
autoxidize to form superoxide and methemoglobin (metHb), the form of Hb containing oxidized 
ferric (Fe3+) iron. Normally metHb levels amount to less than 2% of all circulating Hb. Genetic 
mutations in Hb that increase its propensity to autoxidize, including HbS, and exposure to certain 
oxidizing drugs and toxins can unnaturally increase metHb levels in the body [32, 35].  MetHb is 
unable to bind O2 and is more unstable than oxyHb. MetHb instability leads to an increased risk 
of heme loss and reactive oxygen species (ROS) production [32, 36]. Because of this, there are 
mechanisms within erythrocytes, such as enzymatic conversion of metHb by metHb reductase, to 
ensure that most Hb tetramers are maintained in the oxyHb conformation [32, 37]. In addition to 
O2, Hb is capable of interacting with CO2, carbon monoxide, and nitric oxide (NO) [27]. 
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1.2.3  Pathophysiology 
HbS protein misfolding in RBCs alters the general binding dynamics of Hb tetramers and 
lowers O2 binding affinity. In its deoxygenated state, mutant Hb polymerizes to form long chains, 
forcing affected RBCs into the characteristic sickled shape and reducing their flexibility. This 
reduced flexibility impairs RBC rheology, or flow, through the blood [38, 39]. RBCs can aggregate 
within the vascular system to further impede blood flow and create vaso-occlusive crises in 
patients [39].  
In addition to RBC shape, lipid and membrane dynamics are altered via direct and indirect 
responses to Hb polymerization and corresponding oxidative stress. Many ion channels and 
membrane proteins along the RBC membrane become dysfunctional from recurring cycles of HbS 
polymerization, resulting in cellular dehydration and loss of membrane to form circulating 
microparticles [38, 40]. Large loss of RBC membrane over time allows for significant 
rearrangement of membrane lipid composition, particularly allowing phosphatidylserine 
localization to extend from inner to outer membrane. Exposed phosphatidylserine on circulating 
RBCs increases cellular interactions with other RBCs, white blood cells, and platelets. This can 
cause activation of endothelial cells and coagulation pathways [41]. Endothelial cell activation, in 
turn, increases inflammation by producing pro-inflammatory markers, such as interleukin-6 (IL-
6), and tumor necrosis factor alpha (TNF-α) [38, 42].  Altogether, these mechanisms increase the 
likelihood of further vaso-occlusion.  
Vaso-occlusion and sickled RBC instability lead to a significant increase in hemolysis. In 
fact, the average erythrocyte lifespan in SCD patients is significantly shorter than in healthy 
individuals [43, 44]. While hemolysis is thought to primarily occur outside of the vasculature 
(mediated by macrophage phagocytosis in the spleen), approximately one-third of all hemolysis 
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occurs intravascularly during the resolution of vaso-occlusion [45]. Increased hemolysis generates 
higher concentrations of cell-free Hb and heme in the plasma (estimated concentrations are listed 
in Appendix A Table 3), which can lead to increased oxidative stress. Both Hb and heme can create 
superoxide, ROS, and other oxidative species to induce cellular toxicity as well as vasoconstriction 
[44]. Additionally, cell-free Hb scavenges NO to reduce potential vasodilatory response, further 
worsening blood flow and increasing risk of vaso-occlusion [46]. Although there are carrier 
proteins to sequester cell-free Hb in the serum, such as haptoglobin (Hpt) and hemopexin, the 
expression of these carriers are eventually depleted in many SCD patients [47, 48]. 
Recurring vaso-occlusive crises, accompanied by increased oxidative stress and 
inflammation, function to create clinical manifestations of disease in both the vascular system and 
essentially every organ system of the body (see Appendix A Table 4 for a comprehensive list of 
common SCD complications). SCD patients are generally immunocompromised as much of the 
disease pathology involves the chronic abuse of the body’s immune system and splenic function. 
Because of this, infection has historically been a great concern for patient health and a major cause 
of mortality in patients during infancy [30, 49]. However, with the implementation of SCD 
newborn screening and improved patient treatment, many SCD patients live well into adulthood, 
especially in developed countries like the US. Consequently, with the increase in patients reaching 
adulthood, there is a significant rise in irreversible secondary organ damage and chronic disease. 
1.2.4  Sickle cell nephropathy 
SCN is one of the most common secondary complications in SCD and patients exhibit a 
wide range of renal disease manifestations throughout all stages of life. The severity of SCN should 
not be overlooked as kidney-related injury and disease account for 16-18% of SCD patient 
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mortality [6]. Complications contributing to SCN arise from both vaso-occlusion/hemolysis within 
the kidney microvasculature and oxidative stress/toxicity related to increased cellular exposure to 
free Hb and heme.  
Vaso-occlusion occurs most frequently in the vasa recta of the medulla because of its 
naturally hypoxic environment. Recurring cycles of vaso-occlusion create episodes of ischemia 
that can either result in infarction or resolution and reperfusion of the tissue. Blood flow infarction 
as well as repeated ischemia-reperfusion events can lead to increased oxidative stress, tissue 
dysfunction, and necrosis [6, 50]. Common disease phenotypes linked to this pathology are 
papillary necrosis, hyposthenuria, and hematuria [51-53]. Additionally, renal hyperperfusion and 
hyperfiltration are indirectly connected to these vaso-occlusive events. Although increased vaso-
occlusion impedes blood flow in the microvasculature of the renal medulla, hyperperfusion and 
hyperfiltration predominate whole kidney dynamics. This phenomenon, referred to as the 
perfusion paradox [54], is thought to be caused in part by a vasodilatory effect of increased 
prostaglandin and heme oxygenase-1 (HO-1) expression in response to ischemia and oxidative 
stress [6].  
Glomerular hyperfiltration commonly occurs early in SCD patients before signs of 
glomerular impairment are evident. Hyperfiltration increases the load of protein and solutes 
delivered to the nephron. To compensate, the PT increases its resorptive and metabolic functions 
to maintain glomerulotubular balance. However, the sustainability of this PT hyperfunction is 
difficult and a significant proportion of young SCD patients (~15%) develop tubular proteinuria, 
which is urinary loss of proteins normally filtered by the glomerulus and reabsorbed by the PT 
[10-12]. These patients frequently lack noticeable glomerular damage at diagnosis of tubular 
proteinuria, suggesting that PT dysfunction occurs early in the progression of their kidney disease. 
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PT hypermetabolism and increased oxygen consumption can cause oxidative stress and 
dysfunction in the PT and surrounding interstitial tissue [55]. Early PT dysfunction may also occur 
as a result of increased exposure to free Hb as PT cells are exceptionally sensitive to heme toxicity 
[56-58]. Free Hb is readily filtered by the glomerulus (fractional filtration coefficient of 0.03) and 
delivered to the PT, where it can be taken up through binding to multiligand receptors megalin and 
cubilin [59, 60]. For more information on PT protein resorption and megalin/cubilin binding see 
sections on PT function below.  
Glomerular health and function diminish with age due to the pressure of hyperfiltration and 
targeted injury. Hb and heme generate toxic effects in podocytes to impair their function in 
maintaining the filtration barrier [61]. Additionally, increased levels of endothelin-1, a 
vasoconstrictive signaling peptide, interact with podocytes via the endothelin type A (ETA) 
receptor to further induce injury [62]. As podocyte injury accumulates, glomerular filtration 
becomes leakier. This allows more ions and protein to enter the tubule, further overwhelming PT 
resorptive capacity.  The development of frank proteinuria and albuminuria commonly develop in 
patients as glomerular filtration deteriorates. With continued renal damage and loss of function, 
patients can develop CKD and renal failure. While it is likely that continued renal vascular insult, 
tubular/glomerular dysfunction, and tubulointerstitial damage contribute together to the 
development of CKD, the exact mechanism remains unclear. 
1.2.5  Disease management and treatment 
Although the cause of SCD has been known for approximately 70 years, treatment of the 
disease and its severe complications has proven difficult. The first recommended treatment for a 
secondary complication of SCD was the use of prophylactic penicillin in children to prevent life-
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threatening infection. Penicillin prophylaxis dramatically increased childhood survival rates as its 
use alone has been shown to reduce pneumococcal bacterial infection by 84% in SCD patients 
[63]. Because of the significant increase in childhood SCD survival rate using prophylactic 
penicillin, there has been a great effort to institute universal newborn screening programs for SCD. 
Screening was established across all US states in 2007 [64]. Prevention of infection is critical in 
many SCD patients as elective splenectomy is common to treat mass acute sequestration and 
anemia, forcing patients to be further immunocompromised [1]. 
Currently, there are only two FDA approved drugs to treat SCD: hydroxyurea and Endari®. 
Hydroxyurea, also known as hydroxycarbamide, is a chemotherapeutic drug that increases levels 
of HbF in SCD patients and thus decreases HbS levels to reduce RBC sickling. Hydroxyurea 
treatment has been approved for use in both children and adults and is associated with decreased 
risks of frequent vaso-occlusive crises, acute chest syndrome, and stroke [38, 65]. However, it 
does have limitations in efficacy as increased HbF sustainability varies among patients and patient 
adherence can be poor due to challenges in cost and perceptions of toxicity [66, 67]. Endari® is an 
oral formulation of L-glutamine that functions to increase NADH levels, providing more cellular 
antioxidant activity. Although more studies are needed to determine the long term effects of 
Endari®, it has been shown to decrease frequency of vaso-occlusive crises in patients when used 
alone or in combination with hydroxyurea treatment [68, 69].  
Recurring blood transfusions aid in the prevention of vaso-occlusive crises as donor RBCs 
dilute sickled patient cells. Blood transfusions are also useful in treating anemia and preventing 
stroke in SCD patients. However, chronic transfusions can lead to delayed secondary 
complications, including erythrocyte alloimmunization, increased hemolysis, and iron deposition 
[1, 2]. Additionally, steroids are used to decrease inflammation and analgesics, including 
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nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, are used in an attempt to decrease 
chronic pain. However, continued analgesic use should be used with caution as patient dependence 
and analgesic-induced nephropathy can develop [9].  
Hematopoietic stem cell transplantation has been demonstrated to be curative in a limited 
number of patients. However, this treatment is extremely costly and is currently limited to patients 
with a healthy sibling donor, making it an unlikely option for many [1, 70]. To overcome the need 
for a proper donor candidate, researchers are exploring gene therapy and genome editing 
techniques to alter SCD patient cells. Clinical trials are currently underway using gene therapy, 
including the addition of an anti-sickling HBB gene variant and the deletion of the BCL11A gene 
(partly responsible for repression of γ-globin expression). Additionally, researchers are looking 
into using genome editing techniques to induce γ-globin expression or correct SCD mutation in 
the patient’s genome [71, 72]. While time will only tell if these genetic techniques will provide 
patients with a more permanent treatment of their disease, one known certainty is that gene therapy 
would still be costly, making patient access a continued concern. However, if this form of therapy 
would prove to be curative the price may outweigh the cost of lifelong treatment and burden of 
disease. 
1.2.5.1 Treatment of sickle cell nephropathy 
In addition to prevention of vaso-occlusive crises in SCD patients, targeted treatments for 
SCN have recently emerged. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin 
receptor type II blockers (ARBs) are used to block angiotensin II signaling, which increases 
efferent arteriole dilation and lowers local blood pressure. Preliminary data has shown ACE 
inhibitors and ARBs reduce the frequency of proteinuria in patients [9, 73]. However, adequately 
powered studies are needed to further assess the benefit and determine a recommendation of when 
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to use this treatment. Use of alkalizing agents such as sodium bicarbonate and acetazolamide to 
neutralize acidity in the medulla can increase O2 binding and prevent RBC sickling and hemolysis 
within the kidney [74]. Studies in a SCD mouse model have shown promise in using endothelin-1 
receptor inhibitors to reduce vaso-occlusion and associated kidney damage [75-77]. However, 
clinical trials are needed to test efficacy in humans. 
Once kidney damage has progressed to CKD or ESRD, patients are placed on renal 
replacement therapy, involving hemodialysis and/or kidney transplant. Although SCD is an 
independent risk factor of death in patients receiving new kidneys, patients may have more trouble 
receiving transplants in comparison to age- and race-matched individuals without SCD [78]. 
Additionally, hemodialysis can be very difficult and ineffective for SCD patients as mortality rates 
are 26% higher in comparison to SCD patients pre-dialysis and 2.8 times higher than dialysis 
patients without SCD [79, 80]. 
1.3 Receptor-Mediated Endocytosis in the Proximal Tubule 
Sections within 1.3 are reprinted with minor edits from Annual Review of Physiology, vol. 
79 (1), Megan L. Eshbach and Ora A. Weisz, Receptor-mediated endocytosis in the proximal 
tubule, 425-488, Copyright (2017) with permission from Annual Reviews. 
Epithelial cells that form the PT play an essential role in the retrieval of ions and proteins 
that escape the glomerular filtration barrier. Cells in the proximal convoluted tubule (which 
includes the S1 and S2 segments) express high levels of the multiligand receptors megalin and 
cubilin, which mediate the efficient uptake of low molecular weight (LMW) proteins and other 
ligands from the filtrate. The apical endocytic pathway in PT cells is uniquely specialized to 
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accommodate the high capacity needs of these cells and is acutely and chronically regulated in 
response to changes in ligand exposure. Yet despite the critical role of endocytosis in PT function, 
we know little about how the apical endocytic pathway is organized and regulated in these cells. 
Numerous genetic, acute, and chronic diseases impair the endocytic uptake of filtered ligands by 
PT cells, resulting in tubular proteinuria (aka LMW proteinuria). Megalin and cubilin bind to 
numerous vitamin carrier proteins, and defective uptake of these proteins leads to vitamin 
deficiencies. In many instances, kidney function deteriorates progressively in patients with tubular 
proteinuria. However, it remains unclear whether tubular proteinuria is a marker of PT damage or 
a direct cause of further damage [81]. A better understanding of the PT apical endocytic pathway 
and the consequences of its dysfunction may thus identify new interventional targets to prevent or 
limit kidney disease. 
1.3.1  Multiligand receptors of the proximal tubule 
The multiligand receptors megalin and cubilin coordinate the uptake of most filtered 
proteins and many other small bioactive molecules from the glomerular ultrafiltrate (Fig. 2).  
Megalin (also called gp330 or LRP2) is a member of the low-density lipoprotein receptor 
(LDLR) family of proteins that was originally identified by Kerjaschki & Farquhar as a major 
pathogenic antigen in Heymann nephritis in 1982 [82] and found to be equivalent to brushin, a 
∼600 kDa PT brush border protein previously described by the Muramatsu group [83]. Within the 
kidney, megalin is expressed primarily at the apical surface and in apical endocytic compartments 
of epithelial cells that comprise the S1 segment of the PT, with decreasing expression in the S2 
and S3 segments of the PT. Megalin is also expressed in podocytes, and antigenic responses to 
megalin in these cells is a primary cause of Heymann nephritis in rats [84]. 
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Figure 2. Multiligand receptors in the proximal tubule. 
Megalin and cubilin regulate the uptake of low molecular weight proteins from the glomerular filtrate. The cytoplasmic 
tail of megalin contains two NPXY motifs that bind to the Dab2 clathrin adaptor protein as well as a related NQNY 
sequence implicated in apical delivery. Megalin/cubilin ligands that are filtered through the glomerular barrier are 
listed in Appendix A Table 5. Abbreviations: CUB, complement C1r/C1s, Uegf, Bmp1; Dab2, Disabled-2 protein; 
EGF, epidermal growth factor. 
 
The sequences of rat and human megalin were reported in 1994 and 1996, respectively [85, 
86]. Rat megalin contains 4660 amino acids and is a type I transmembrane protein with a large 
lumenal domain that contains 36 LDLR ligand binding complement type repeat motifs clustered 
into four domains. These domains are interspersed with epidermal growth factor (EGF)-type 
repeats and beta propeller spacers characterized by YWTD motifs that mediate ligand dissociation 
in acidified compartments (see reference [87] for an excellent review on the structure and function 
of LDLR family member domains). The cytoplasmic tails of all LDL receptor family members are 
divergent other than the presence of two NPXY motifs that mediate endocytosis; in addition, 
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megalin contains an additional NPXY-like motif VENQNY that may be important for apical 
delivery of the protein [88]. Similar to other members of the LDLR family, megalin also contains 
an RXRR motif that can be cleaved by furin and related proteases. Cleavage at this site could 
explain the soluble form observed associated with cells and secreted into the urine [89]. Megalin 
was also demonstrated to undergo regulated intramembrane proteolytic cleavage [90]; however, 
the physiological significance of this is unclear [91, 92].  
Folding and biosynthetic trafficking of megalin are facilitated by its interaction with the 
chaperone receptor-associated protein (RAP) that is localized primarily to the endoplasmic 
reticulum. RAP also accompanies megalin to the plasma membrane [93, 94] and dissociates from 
the receptor in acidified compartments [95]. RAP also interacts with the LDLR-related protein 
LRP. It was proposed that binding to RAP prevents premature interaction of megalin with ligands 
along the biosynthetic pathway [94].  
Early studies aimed at identifying the function of megalin demonstrated that it interacts 
with several proteins that also bind to LRP, including ApoE and lipoprotein lipase. Since then, 
interaction of megalin with an increasing number of filtered ligands has been reported [96]. An 
essential role for megalin in the uptake of filtered proteins was cemented in 1996 by the 
demonstration that mice lacking megalin exhibit tubular proteinuria [97] and by the observation 
that RAP competes with albumin for uptake in microperfused tubules [98].  
Whereas megalin can bind to many ligands independently, it may require a coreceptor for 
some interactions. Cubilin is a 460 kDa receptor expressed abundantly in the PT that interacts with 
megalin and increases the multiligand binding capability of the complex. Cubilin was originally 
identified as the receptor for intrinsic factor-vitamin B12 complex in the intestine [99] and was 
subsequently shown to be identical to a previously described antigen that localized to coated pits 
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in the rat PT [100, 101]. The receptor was cloned from rat yolk sac in 1998 and named cubilin 
based on the presence of 27 tandem CUB (complement C1r/C1s, Uegf, Bmp1) domain repeats that 
encompass the majority of the protein sequence [102]. Unlike megalin, cubilin has no 
transmembrane domain and requires megalin for its association with the membrane. Cubilin binds 
to several of the proteins recognized by megalin, including albumin, Hb, RAP, and Ig light chains. 
Appendix A Table 5 lists the ligands known to be retrieved by the PT through their interactions 
with megalin and cubilin. In addition, cubilin may also bind to other proteins that do not bind to 
megalin, including transferrin, intrinsic factor-vitamin B12 complex, and apoA1. Cubilin-specific 
ligands were originally identified in the urine of dogs with mutations in cubilin and in patients 
with Imerslund-Gräsbeck syndrome, who have vitamin B12 malabsorption. However, there may 
be some species-specific differences in cubilin binding selectivity, as unlike dogs lacking 
functional cubilin, cubilin knockout mice showed no increase in urinary excretion of transferrin or 
apoA1 [103, 104].  
Cubilin also interacts with amnionless, a 38–50 kDa transmembrane protein that, similar 
to megalin, contains cytoplasmic NPXY motifs that direct internalization. Amnionless appears to 
be essential for cubilin transport to the apical surface, as cubilin is retained intracellularly in PT 
cells of amnionless knockout mice [105]. Mutations in amnionless also cause Imerslund-Gräsbeck 
syndrome [106]. Cubilin binds simultaneously to megalin and amnionless [107], but whether and 
how these three proteins interact functionally at the apical membrane of PT cells remain unclear.  
More recently, the ubiquitously expressed MHC-related Fc receptor for IgG (FcRN) has 
also emerged as a potential receptor that participates in IgG and albumin recovery from the 
ultrafiltrate. This heterodimeric receptor, comprising an MHC class I-like α chain and its 
obligatory β2-microglobulin subunit, binds independently to IgG and to albumin at acidic pH but 
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not at neutral pH. FcRN is known to play an important role in salvaging serum IgG and albumin 
in many nonrenal tissues (reviewed in [108]). The current model in these cells is that these proteins 
are taken up by pinocytosis and bind to FcRN in acidified compartments. Proteins that bind to 
FcRN escape the default route to the degradative pathway and are instead recycled to the cell 
surface where the increase in pH causes them to be released. Consistent with this model, FcRN 
knockout mice have half the levels of serum albumin as normal mice, apparently due to increased 
degradation kinetics [109].  
FcRN is expressed abundantly in the glomerulus and PT of the kidney. Within the 
glomerulus, FcRN is expressed at the surface of podocytes and may function to scavenge albumin 
and immunoglobulins from the basement membrane to limit clogging of the filtration barrier  
[110]. In contrast, in the PT, FcRN binds to soluble albumin that dissociates from megalin/cubilin 
in acidified endocytic compartments and delivers it via transcytosis to the basolateral surface for 
reentry into the plasma [111]. The extent to which this pathway in the PT contributes to the 
maintenance of serum albumin levels remains controversial. One contested parameter is the 
amount of albumin that actually reaches the PT (nicely reviewed in [112]). Another key issue that 
remains to be addressed is the extent to which transcytosis of albumin occurs in the kidney, and 
how much of this is mediated by FcRN. Tenten et al. [111] attempted to address the role of FcRN-
mediated transcytosis of postfiltered albumin by observing the appearance in serum of tagged 
albumin expressed selectively in podocytes of control and FcRN knockout mice. Although tagged 
albumin could be detected in the serum, the capacity of this salvage pathway relative to the 
degradative pathway in PT cells could not be assessed in this study. Of note, earlier studies 
assessing the fate of radioiodinated albumin in HK-2 human proximal kidney cells, perfused ex 
vivo rat kidneys, and microperfused rabbit PTs concluded that the majority of internalized albumin 
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was degraded rather than transcytosed to the basolateral surface [113, 114]. On balance, the 
evidence to date remains consistent with the idea that PT reclamation of albumin represents a 
relatively low-level salvage pathway to recover a small amount of filtered protein rather than a 
high capacity transcytotic pipeline necessary to maintain serum albumin levels. 
1.3.2  Clathrin-dependent endocytosis 
The apical endocytic pathway in PT cells is highly specialized for robust internalization 
and is uniquely organized for this function [115]. Moreover, the capacity for apical endocytosis is 
both acutely and chronically flexible, as described further in later sections. The preference for 
apically driven endocytosis and the consequent organization of the endocytic pathway is 
recapitulated to differing extents in primary and immortalized cell culture models of the PT [116-
118]. Although in vivo studies have provided a detailed morphological description of the PT 
endocytic pathway, the lack of an ideal cell culture model system has hampered our ability to 
understand how endocytosis and recycling are regulated at the molecular level in these cells. To 
date, our most detailed information about the organization, cellular machinery, and regulation of 
the apical endocytic pathway in polarized kidney epithelial cells comes from studies conducted in 
Madin-Darby canine kidney (MDCK) cells, which maintain a limited apical endocytic capacity 
and are not considered a representative model of the PT (Fig. 3). Many PT cell culture models do 
exist, however, but most are poorly differentiated and lack the apical microvilli characteristic of 
the PT brush border. Others exhibit relatively poor megalin expression and/or apical endocytic 
capacity and may better represent S2 or S3 segments of the PT. At present, the opossum kidney 
(OK) cell line remains the preferred cell culture model for the S1 segment of the PT, as it most 
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closely recapitulates PT ion transport functions, expresses megalin, retains a robust apical 
endocytic capacity, and is well differentiated. 
 
Figure 3. The apical endocytic pathway in MDCK and proximal tubule cells. 
(a) Cargo internalized from the apical and basolateral surface of MDCK cells via clathrin-coated pits enters Rab5-
positive AEEs and BEEs, respectively. Most proteins return to the plasma membrane from these compartments via a 
Rab4-dependent fast recycling pathway, but they may also be delivered to Rab11-positive AREs or Rab8-positive 
CREs. Ligands released from internalized receptors in acidified early endosomes are transported to Rab7-positive 
MVBs and eventually to lysosomes. (b) In PT cells, apical proteins are internalized in irregular clathrin-coated 
invaginations into apical early endosomes that fuse to form larger AVs. Recycling of membrane proteins can occur 
from AEEs or AVs via DATs, whereas soluble components of AVs are delivered to lysosomes. The Rab proteins and 
other machinery associated with these compartments remain largely unknown. Abbreviations: AEE, apical early 
endosomes; ARE, apical recycling endosomes; AV, apical vacuole; BEE, basolateral early endosomes; CRE, common 
recycling endosomes; DAT, dense apical tubules; MDCK, Madin-Darby canine kidney; MVB, multivesicular bodies; 
PT, proximal tubule. 
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1.4 Vitamin D Metabolism 
Vitamin D metabolism is a highly regulated, multiorgan process (outlined in Appendix A 
Fig. 18). First, prohormone vitamin D is produced in the skin through conversion from 7-
dehydrocholesterol upon ultraviolet irradiation and thermal rearrangement or is absorbed from a 
diet that includes dairy products and/or fish oils. Vitamin D is then transported to the liver where 
it is converted to 25-hydroxyvitamin D [25(OH)D], which is the primary circulating vitamin D 
metabolite by concentration [119]. Although not hormonally active just yet, 25(OH)D serum 
concentration is used as the most reliable biomarker of vitamin D status because of its normally 
high concentration and long half-life (approximately 2-3 weeks) [120-122]. Of note, DBP and 
albumin, the two vitamin D metabolite carriers, are also produced in the liver [123]. Vitamin D 
metabolites are estimated to be 85-90% bound to DBP, 10-15% bound to albumin, and less than 
1% unbound in the serum, suggesting these carrier proteins play a large role in both vitamin D 
transport and availability. In particular, DBP plays a large role in vitamin D availability as vitamin 
D metabolite affinity for DBP is much higher than albumin and only metabolites that are unbound 
or bound to albumin are considered bioavailable [16]. 
At any given time DBP is primarily bound to 25(OH)D. This is because 25(OH)D is most 
abundant in the serum and DBP binds 25(OH)D with greater affinity than other vitamin D 
metabolites [124]. DBP travels to the kidney where it binds to megalin/cubilin receptors to enter 
PT cells. Once inside PT cells, DBP is degraded in lysosomes, and any associated 25(OH)D is 
trafficked to mitochondria for activation. The mitochondrial enzyme 25-hydroxyvitamin D-1 alpha 
hydroxylase (CYP27B1) converts 25(OH)D to its metabolically active form 1,25-
dihydroxyvitamin D [1,25(OH)2D] (Fig. 4). After activation, 1,25(OH)2D is released on the 
basolateral side of PT cells to enter the bloodstream for distribution to target tissues [125].  
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Figure 4. Vitamin D trafficking and metabolism in the proximal tubule cell. 
Vitamin D-binding protein (DBP) carrying 25(OH)D binds to megalin and cubilin receptors and enters PT cells via 
endocytosis. Once inside cells, 25(OH)D-DBP is sorted and trafficked to lysosomes and megalin and cubilin are 
recycled back to the surface for continued endocytosis. DBP is degraded in lysosomes and 25(OH)D is trafficked to 
the mitochondria. Mitochondrial vitamin D hydroxylases CYP27B1 and CYP24A1 metabolize 25(OH)D. CYP27B1 
converts 25(OH)D to its active form 1,25(OH)2D. CYP24A1 converts 25(OH)D to 24,25(OH)2D, which is thought 
to be targeted for degradation. The conversion of 25(OH)D is dependent on concentrations of circulating 
1,25(OH)2D. 
 
While several extra-renal tissues are reported to express CYP27B1, the PT is the primary 
site for vitamin D activation [16]. Several disease models have provided compelling data to support 
the importance of PT-specific vitamin D activation. Anephric patients have extremely low and 
sometimes undetectable 1,25(OH)2D serum levels [126]. Megalin knockout mice lose DBP in 
urine and develop vitamin D deficiency and consequent bone disease [97, 127]. Cubilin-deficient 
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dogs also exhibit lower serum levels of vitamin D [25(OH)D and 1,25(OH)2D] [128]. Patients with 
Dent disease, caused by a mutation in an antiporter involved in PT endocytosis, have low vitamin 
D levels and frequently develop bone disease [129]. 
1.4.1  Vitamin D signaling in the proximal tubule 
In target cells of vitamin D signaling, bioavailable 1,25(OH)2D interacts with vitamin D 
receptor (VDR) in the nucleus to enact transcriptional alteration [119]. VDR binds at vitamin D 
response elements (VDREs) in DNA to cause enhancement or inhibition of gene transcription 
depending on VDRE location [130]. While VDR cellular localization has been identified outside 
of the nucleus, including along the apical brush border of PT cells [131], the function of this VDR 
pool is widely debated. Additionally, it is still unclear how 1,25(OH)2D enters the nucleus of target 
cells, especially those not expressing megalin or cubilin, to enact transcriptional regulation [16]. 
However, PT cells are known to express VDR, both in and outside of the nucleus, and 
megalin/cubilin receptors, enabling 1,25(OH)2D transport into the cell and nucleus to perform 
transcriptional regulation. In fact, 1,25(OH)2D signaling in the PT is imperative in the regulation 
of continued vitamin D metabolism.  
Overall, VDR signaling in the PT works as a feedback loop to reduce vitamin D activation. 
This is accomplished primarily through decreased expression of CYP27B1 and increased 
expression of another mitochondrial enzyme 1,25-dihydroxyvitamin D 24-hydroxylase 
(CYP24A1). Decreased CYP27B1 expression reduces 1,25(OH)2D production. Increased 
CYP24A1 expression expedites 1,25(OH)2D and 25(OH)D breakdown as 24-hydroxylated 
metabolites, 1,24,25(OH)3D and 24,25(OH)2D are thought to be degradation products [119]. VDR 
signaling has also been reported to affect expression of PT receptors megalin and cubilin. In PT 
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cells grown in culture, addition of 1,25(OH)2D increased megalin and decreased cubilin expression 
[132, 133]. However, it is unknown whether these transcriptional changes ultimately affect PT cell 
endocytic uptake of DBP and other proteins. 
1.4.2  Vitamin D immunomodulation and its effects on inflammation in sickle cell disease 
Recent research has begun to emerge demonstrating several immunomodulatory effects of 
vitamin D signaling, particularly in the suppression of the adaptive immune system. Vitamin D 
signaling diminishes the adaptive immune response in several ways. It reduces dendritic cell 
maturation and macrophage antigen presentation [134-137]. Additionally, vitamin D signaling 
promotes T cell differentiation into T helper cell type 2 (Th2) and regulatory T (Treg) cells rather 
than T helper cell type 1 (Th1) and T helper cell type 17 (Th17) cells [137-140]. This change in 
immune cell differentiation reduces inflammation by increasing anti-inflammatory and decreasing 
pro-inflammatory cytokine expression (Appendix A Fig. 19) [141-143]. 
Chronic inflammation is very common in SCD and is thought to be partly caused by 
cytokine dysregulation, resulting in increased pro-inflammatory and decreased anti-inflammatory 
cytokine expression. Vitamin D signaling also alters the expression of many of these same 
dysregulated cytokines, including IL-6, IL-10, IL-17, IL-4, and TNF-α [19, 144-146], to suppress 
an inflammatory response. This suggests an important role for vitamin D in the deterrence of 
inflammation in SCD. SCD patients are commonly vitamin D deficient and low vitamin D status 
is reportedly associated with several comorbidities, including vaso-occlusive crisis [18, 147]. 
Additionally, vitamin D supplementation has already been demonstrated to be useful in the 
treatment of inflammation in other diseases, including acute congestive cardiac failure and 
autoimmune cytopenias [148, 149], and has been reported to decrease pro-inflammatory cytokine 
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expression in SCD patients [19]. However, very few studies have focused on vitamin D 
supplementation in SCD and there is a need for more comprehensive study to determine the full 
benefits of supplementation and treatment recommendations. 
1.5 Specific Aims 
While there has been a great deal of progress in the treatment of acute complications in 
SCD, treatment of chronic secondary complications, including SCN, is lacking. Patients that 
develop SCN have minimal treatment options and a very poor prognosis once their disease has 
progressed to CKD. A common symptom in young SCD patients is tubular proteinuria, which is 
indicative of PT dysfunction early in the progression of SCN. PT dysfunction may also be a factor 
in low vitamin D status commonly observed in SCD patients as the PT is the primary site of vitamin 
D activation. Since the PT is known to be sensitive to heme toxicity and patients exhibit increased 
levels of cell-free Hb chronically and during hemolytic crisis, PT dysfunction is thought to be 
associated with increased Hb exposure although the pathophysiology is unclear. 
The purpose of this dissertation is to identify any correlation between increased cell-free 
Hb concentrations and PT dysfunction in the context of SCD. Understanding the mechanism of 
PT dysfunction and tubular proteinuria development could help to identify early biomarkers and 
possible therapeutic targets before considerable progression of kidney damage occurs in patients. 
Additionally, preventing PT dysfunction may have significant contributions in maintaining patient 
vitamin D levels, which could further improve patient outcomes as vitamin D is shown to 
negatively regulate inflammation. I hypothesized that increased Hb levels inhibit PT protein 
uptake to cause tubular proteinuria. Along with inhibition of DBP uptake, I hypothesized that PT 
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cell toxicity from increased Hb exposure prevents proper vitamin D metabolism and signaling to 
contribute to vitamin D deficiency. I tested my hypotheses in the following specific aims: 
 
1. Characterize the inhibitory role of Hb on protein endocytosis by PT cells.  
2. Define the effects of Hb exposure on the metabolism of vitamin D in PT cells.  
3. Characterize the effects of decreased vitamin D levels on endocytosis in the PT. 
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2.0 Materials And Methods 
2.1 Cell Culture 
All cell culture reagents were from Sigma unless otherwise specified. Opossum kidney 
(OK) cells (Didelphis virginiana, adult female, kidney cortex) were cultured in DMEM/F12 
medium with either 10% (all experiments in chapter 3 and uptake experiments in chapter 4) or 5% 
(non-uptake experiments in chapter 4 and all experiments in chapter 5) FBS (Atlanta Biologicals) 
and 5 mM GlutaMAX (GIBCO). HK-2 cells (Homo sapiens, adult male, cortex/proximal tubules, 
papilloma immortalized) were cultured in DMEM/F12 with 5 µg/ml insulin, 0.02 µg/ml 
dexamethasone, 0.01 µg/ml selenium, 5 µg/ml transferrin, 2 mM L-glutamine, and 10% FBS 
(Atlanta Biologicals). LLC-PK1 cells (Sus scrofa, male, kidney epithelium) were cultured in 
DMEM/F12 medium with 10% FBS (Atlanta Biologicals) and 5 mM GlutaMAX (GIBCO). 
2.2 Quantitation and Imaging of Endocytosis 
2.2.1  Measurement of a single fluorescently-tagged protein uptake in the presence of 
unlabeled protein competition 
In experiments measuring the uptake of a single protein HK-2 (5 × 105), LLC-PK1 (5 × 
105), or OK (4 × 105) cells were plated in duplicate to triplicate samples on 12-mm Transwell (0.4 
µm pore) polycarbonate membrane inserts (Corning) in a 12-well plate, with 0.5 ml apical and 1.5 
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ml basolateral culture medium. The following day, cells were transferred to an orbital shaker set 
at 74–146 rpm in the incubator and allowed to grow for an additional 3-4 days with daily medium 
changes. Studies in our lab demonstrate that chronic exposure to orbital shear stress enhances cell 
differentiation and endocytic capacity [150].  
For experiments measuring albumin uptake, cells were incubated with apically added 0.6 
µM Alexa Fluor 647-BSA (Thermo Fisher Scientific) and unlabeled Hb or L-NAME (30 min 
pretreatment) as indicated in DMEM/F12 medium with 25 mM HEPES (GIBCO) for 1 h at 37°C 
under continuous orbital rotation. For endocytosis studies in Fig. 9B, oxyHb and Hpt (Athens 
Research and Technology) were added to cells as indicated 30 min prior to addition of albumin. 
In experiments measuring uptake of Hb uptake, cells were incubated with 2 µM Alexa Fluor 568-
conjugated Hb for 1 h at 37°C under orbital shear stress in the presence of unlabeled albumin or 
oxyHb as specified.  
Purified DBP (GC-Globulin; Athens Research & Technology) and RBP (RBP4; Athens 
Research & Technology) were labeled with Alexa Fluor-647 using the Protein Labeling Kit 
(Invitrogen) according to the manufacturer’s instructions. Cells were incubated with DBP (25nM 
in OK cells; 500nM in LLC-PK1 cells) or RBP (100nM in OK cells; 500nM in LLC-PK1 cells) 
for 1 h at 37°C under orbital shear stress alone or in the presence of unlabeled oxyHb as specified.  
To quantify the uptake of fluorescent ligands, filters were washed 3-5 times with cold PBS 
containing Ca2+ and Mg2+, solubilized in 300 µl 20 mM MOPS, pH 7.4/0.1% Triton X-100 for 30 
min shaking at 4°C, and fluorescence was quantified using the GloMax Multi-Detection System 
(Promega). Cells on filters used for imaging were washed, fixed in 4% paraformaldehyde, and 
imaged using a Leica TCS SP5 confocal microscope. Maximum projections of confocal stacks 
were created in FIJI. 
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2.2.2  Measurement of two fluorescently-tagged proteins differential uptake  
In experiments measuring the dual uptake of two fluorescently-tagged proteins OK (6 × 
104) cells were plated in sextuplicate samples on a glass-bottomed, black-welled 96 well plate 
(PerkinElmer) with 200ul medium. Cells were cultured for two days with daily medium changes. 
Cells were then incubated with apically added 0.6 µM Alexa Fluor 647-BSA or 25nM Alexa Fluor 
647-DBP and Alexa Fluor 488-conjugated Hb in a range of concentrations (0.6 – 20 µM) as 
indicated in 50uL DMEM/F12 medium with 25 mM HEPES for 2 h at 37°C.  
To quantify the uptake of fluorescent ligands, filters were washed five times with cold PBS 
containing Ca2+ and Mg2+, solubilized in 150 µl 20 mM MOPS, pH 7.4/0.1% Triton X-100 for 30 
min shaking at 4°C, and fluorescence of each protein was quantified sequentially using the GloMax 
Multi-Detection System (Promega). 
2.2.3  Measurement of protein uptake after changes in 1,25(OH)2D exposure 
LLC-PK1 (5 × 105) or OK (4 × 105) cells were plated in triplicate samples on 12-mm 
Transwell (0.4 µm pore) polycarbonate membrane inserts (Corning) in a 12-well plate, with 0.5 
ml apical medium and 1.5 ml basolateral medium. The following day, cells were transferred to an 
orbital shaker set at 146 rpm in the incubator and allowed to grow for an additional 3-4 days with 
daily medium changes. On the final culture day, cells were incubated in serum-free medium with 
or without 1,25(OH)2D (Tocris) present. After 24 h of 1,25(OH)2D exposure, cells were incubated 
with fluorescently-labeled proteins and protein uptake was quantified as described above in section 
2.2.1. 
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2.3 Hemoglobin Preparation and Quantitation 
Hemoglobin A (HbA) was isolated from expired RBC units as described [151, 152]. Sickle 
hemoglobin (HbS) was obtained from Sigma. Hb concentration and oxidation state was determined 
by spectral deconvolution using HbA standard spectra for met, oxy, and deoxy species as 
previously reported [151, 152]. Hb concentrations were calculated per mole of heme. Hb was 
conjugated to Alexa Fluor 568 or Alexa Fluor 488 using the Protein Labeling Kits (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. 
2.4 Sequence and Structure Analysis 
Sequences of human Hbα, Hbβ, and albumin were retrieved from UniProt (Hb α P69905, 
Hb β P68871, Albumin P02768). We compared the solvent accessible surfaces of the Hb dimer in 
the absence and in the presence of Hpt as observed in the Hpt-Hb complex (PDB: 4F4O) [153]. 
The sequences for the individual helices that form the main interactions with Hpt (Hb α helices G 
and H, and Hb β helices G and H) were aligned against the sequence of human albumin using the 
BLAST and CLUSTAL W software [154, 155]. The sequences identified in human albumin were 
compared with the available structure of human albumin (PDB: 3SQJ) [156] to evaluate secondary 
structure conservation. Protein structures and electrostatic surface potentials were generated with 
PyMOL Molecular Graphics System (2002) (DeLano Scientific, San Carlos, CA). 
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2.5 Aconitase Activity 
LLC-PK1 (2 × 106), or OK (1.6 × 106) cells were plated in singlet to duplicate samples on 
24-mm Transwell (0.4 µm pore) polycarbonate membrane inserts (Corning) in a 6-well plate, with 
1.5 ml apical and 2.5 ml basolateral medium. The following day, cells were transferred to an orbital 
shaker set at 146 rpm in the incubator and allowed to grow for an additional 3-4 days with daily 
medium changes. During this time cells were exposed to Hb (oxyHb or metHb) at concentrations 
and time periods as indicated. 
Cells were washed twice with ice-cold PBS, scraped off filters, and pelleted. Cell pellets 
were then lysed in 150 µL assay buffer by passage through a 22-gage needle 10 times. Aconitase 
was collected by sequential centrifugation at 3,000 rpm (2 × 10 min) and 12,000 rpm (1 × 10 min) 
and collection of supernatant. Aconitase activity was measured using the Aconitase Activity 
Colorimetric Assay Kit (BioVision) according to the manufacturer’s instructions. Aconitase 
activity was normalized to total protein within each sample. 
2.6 Quantitative PCR (qPCR) Analysis 
OK (4 × 105) cells or LLC-PK1 (5 × 105) cells cultured as above (section 2.2.1) in the 
presence of Hb (oxyHb or metHb) or 1,25(OH)2D at concentrations and time periods as indicated. 
Cells were collected using Accutase (Sigma) and RNA was extracted using the Ambion PureLink 
RNA mini kit (ThermoFisher) according to the manufacturer’s protocol. LLC-PK1 cell total RNA 
was treated with RQ1 Rnase-Free Dnase (Promega) according to the manufacturer’s protocol. 
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cDNA was synthesized from 1 µg total RNA using Reverse Transcriptase, High Capacity cDNA 
Kit (Life Technologies). 
Gene expression was measured by qPCR using the iTaq Universal SYBR Green Supermix 
500 (Bio-Rad) on a CFX ConnectTM Real-Time PCR Detection System (Bio-Rad). Gene primers 
used in experiments are listed below in Table 1. The expression of each gene was normalized to 
ACTB expression and relative fold change (RFC) was calculated using the equation 𝐹𝐹𝐹𝐹 = 2𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿 , 
where 𝛿𝛿𝛿𝛿𝐹𝐹𝐶𝐶 = 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝛿𝛿𝐹𝐹𝐶𝐶 − 𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝑡𝑡𝑐𝑐𝑐𝑐 𝛿𝛿𝐹𝐹𝐶𝐶 and 𝛿𝛿𝐹𝐹𝐶𝐶 = 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝐹𝐹𝐶𝐶 − 𝐴𝐴𝐹𝐹𝐴𝐴𝐴𝐴 𝐹𝐹𝐶𝐶. 
 
Table 1. qPCR primers used in experiments. 
Cell 
line Gene Forward primer (5’3’) Reverse primer (5’3’) 
O
K
 
CUBN AAGAAGGAAAGGTCCTGCATGT GTTCAGGAGGGTGACTAGAGC 
LRP2  AGGCTCCCTTCTGCCATCTCTTC GCAGAATCTGGTCCAAAACCTGACAC 
CYP24A1 CCCCAGTGGAGCTTCACAAA TTCTTCTGCACCCGTGGATT 
CYP27B1 ACGGTCTCCAACACACTGTC TGACGTAATCACCCACACGG 
ACTB AGTACCCCATTGAACACGGT GTCTCAAACATGATCTGTGTCATCT 
LL
C-
PK
1 CUBN CCGGAGAGTGTGTCCAGAAC GCCCAGGTCAAGCGGAG LRP2 CTGCTCTTGTAGACCTGGGTTC TCGGCACAGGTACACTCATAAC 
CYP24A1 ATGAGAAGAGATTTGGGCTCC GTCACAGACGCATACAATTCC 
CYP27B1 CAGTGTGGTTGGCCAGTTTC GCCTCTGCCATTCTTCACCT 
ACTB CCAGATCATGTTCGAGACCTTC TCTTCATGAGGTAGTCGGTCAG 
2.7 Western Blot Analysis 
2.7.1  Heme oxygenase 1 expression 
HK-2 (5 × 105) cells were cultured as above (section 2.2.1) in the presence of 50 µM 
OxyHb for the indicated periods, then washed, solubilized, and equivalent amounts of total protein 
were separated by SDS-PAGE on 4–15% Criterion TGX gels (Bio-Rad).  Samples were blotted 
33 
using rabbit polyclonal anti HO-1 antibody (1:1,500; Abcam ab137749) and mouse monoclonal 
β-actin antibody (1:5,000; Sigma A1978). 
2.7.2  CYP24A1 and CYP27B1 expression 
OK (4 × 105) cells were cultured as above (section 2.2.1) for 24 h or 72 h in the presence 
of Hb (oxyHb or metHb) at the indicated concentration and time periods. Cells were then washed, 
solubilized, and lysates were normalized by total protein. Equivalent amounts of total protein were 
separated by SDS-PAGE on 4–15% Criterion TGX Stain-FreeTM gels (Bio-Rad). Samples were 
blotted using rabbit polyclonal anti CYP24A1 antibody (1:1,000; LifeSpan BioSciences, Inc. LS-
C407760) and rabbit polyclonal anti CYP27B1 antibody (1:700; LifeSpan BioSciences, Inc. LS-
C407761).  
2.7.3  Megalin and cubilin expression 
OK (4 × 105) cells or LLC-PK1 (5 × 105) cells were cultured as above (section 2.2.3). Cells 
were then washed, solubilized, and lysates were normalized by total protein. Equivalent amounts 
of total protein were separated by SDS-PAGE on 3–8% Criterion XT Tris-Acetate gels (Bio-Rad). 
Samples were blotted using rabbit polyclonal anti-megalin antibody (1:5,000; MC-220, gift from 
Dan Biemesderfer). OK cells were blotted using rabbit polyclonal anti-cubilin antibody (1:1,000; 
designed against opossum epitope in collaboration with Lampire Biological Products). LLC-PK1 
cells were blotted using rabbit polyclonal anti-cubilin antibody (1:1,000; Biorbyt orb4997). 
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2.8 Statistical Analysis and Graphical Representation 
Statistical analysis was completed using StataSE 15 (StataCorp. 2017. Stata Statistical 
Software: Release 15. College Station, TX: StataCorp LLC). Experiment-to-experiment variability 
was assessed as a possible confounder in all experiments. If this variability was significant, it was 
factored in as a covariate when determining significance of experimental conditions via ANCOVA 
analysis followed by pairwise comparison. Additionally, in these experiments graphed data were 
normalized by dividing each data point by its experimental mean to allow a clearer view of data 
trends. All graphics were generated using GraphPad Prism version 7.03 (GraphPad Software, La 
Jolla California USA). 
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3.0 Hemoglobin Inhibits Albumin Uptake by Proximal Tubule Cells: Implications for 
Sickle Cell Disease 
Reprinted with minor edits from American Journal of Physiology – Cell Physiology, vol. 
312 (6), Megan L. Eshbach, Amandeep Kaur, Youssef Rbaibi, Jesús Tejero, and Ora A. Weisz, 
Hemoglobin inhibits albumin uptake by proximal tubule cells: implications for sickle cell disease, 
C733-C740, Copyright (2017), with permission from American Physiological Society. 
3.1 Introduction 
SCD is a devastating disease resulting from a single mutation (Glu7Val) in Hb that causes 
RBCs to assume a rigid curved shape that blocks their passage through the vasculature. Obstruction 
of capillaries by sickled RBCs results in ischemia, severe pain, and necrosis. Additionally, RBCs 
in SCD patients are susceptible to hemolysis, resulting in chronically elevated plasma levels of 
free Hb that can skyrocket during hemolytic crises [30]. Free Hb in the circulation can scavenge 
NO produced by endothelial cells, leading to vasoconstriction that compounds vaso-occlusion 
[157]. Exposure of cells to heme proteins also triggers the production of cytotoxic ROS [157]. 
With the development of treatment regimens to increase life expectancy, kidney 
manifestations of SCD have become increasingly appreciated. There are numerous renal 
complications in SCD, including glomerulopathy, acute kidney injury, CKD, impaired urinary 
concentrating ability, and distal nephron dysfunction. Kidney disease currently accounts for >15% 
of mortality in SCD patients [6]. These complications are due in part to the propensity of RBCs to 
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sickle in the hypoxic renal medulla. However, exposure of kidney cells to Hb liberated during 
hemolysis also plays an important role in the progression of renal disease. Released Hb dimers 
(consisting of α- and β-globin chains, each with molecular mass ~16 kDa) are readily filtered into 
the tubule lumen with a fractional filtration coefficient of 0.03 [59]. At the normal plasma level of 
Hb of 3 mg/dl (2 µM), the concentration in the glomerular ultrafiltrate entering the kidney tubule 
lumen is very low, ~60 nM. However, plasma concentrations of Hb are chronically about tenfold 
higher in SCD patients, and during hemolytic crisis, the concentration of plasma Hb can approach 
1 g/dl, resulting in tubular concentrations above 15 µM [158]. 
Filtered Hb is taken up by the multiligand receptors megalin and cubilin, which are 
abundantly expressed in the S1 segment of the kidney PT [96]. Previous studies show that Hb 
binds to megalin and cubilin with relatively high affinity (1.7 µM and 4.1 µM, respectively [60]). 
Megalin and cubilin also bind with comparable affinities to a large number of other filtered low-
molecular-weight (LMW) proteins and other ligands, including DBP, intrinsic factor-cobalamine 
(vitamin B12), and parathyroid hormone [159]. In addition, megalin and cubilin take up the low 
level of albumin that normally escapes the glomerular filtration barrier. Disruption of the apical 
endocytic pathway leads to tubular proteinuria, that if left unchecked can trigger inflammation and 
fibrosis resulting in end-stage renal disease [13]. 
The PT is known to be especially sensitive to heme toxicity, and cytoprotective responses 
(upregulated expression of ferritin, ferroportin, heme oxygenase-I, heme oxygenase-II, Hpt, and 
hemopexin) have been well characterized in response to heme-induced injury [56, 57]. Consistent 
with this, tubular proteinuria has been reported in a significant fraction of SCD patients, and 
particularly in younger patients [10-12]. These patients also exhibit increased excretion of urinary 
biomarkers characteristic of tubular injury [160]. Tubular proteinuria in these patients frequently 
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occurred independently of glomerular dysfunction, suggesting that PT injury is an initiating step 
in the cascade leading to CKD in SCD patients. 
PT function, including the uptake of filtered megalin/cubilin ligands, is highly responsive 
to changes in fluid shear stress that accompany tubular flow [161, 162]. Because NO mediates 
mechanosensitive responses in endothelial cells, we wondered whether Hb released into the tubule 
lumen during hemolytic crises might scavenge NO to impair apical endocytosis. To test this, we 
assessed whether exposing PT cells to levels of Hb expected during SCD crisis affects uptake of 
albumin. We found that Hb inhibits albumin uptake by PT cells in a dose-dependent manner. 
Surprisingly, the effect of Hb is independent of any effect on NO and instead results from direct 
competition for uptake by megalin/cubilin receptors. Impaired uptake of normally filtered 
megalin/cubilin ligands uptake during hemolytic crisis may explain clinical manifestations of SCD 
of unknown etiology. 
3.2 Results 
3.2.1  Hemoglobin inhibits receptor-mediated albumin uptake by proximal tubule cells. 
To test whether the NO scavenging by Hb affects PT endocytosis, we incubated polarized 
OK cells for 1 h with apically added 0.6 µM Alexa Fluor 647-albumin in the presence or absence 
of 50 µM OxyHb, MetHb, or CNMetHb. These three forms of Hb have different NO scavenging 
potential, with OxyHb being significantly more potent [163]. As an additional control, we also 
pretreated cells for 30 min with the NOS inhibitor L-NAME (L-NG-nitroarginine methyl ester, 
100 µM) before adding fluorescent albumin. Cells were then washed extensively, and cell-
38 
associated albumin was visualized in fixed cells by confocal microscopy (Fig. 5A) or quantified 
by spectrofluorimetry (Fig. 5B). As we previously demonstrated, Alexa Fluor 647-albumin readily 
accumulated in intracellular vesicular compartments in OK cells [161]. Addition of any of the 
three forms of Hb during the albumin incubation profoundly inhibited the uptake of albumin by 
PT cells. In contrast, L-NAME had no apparent effect on albumin uptake. Quantitation of albumin 
uptake by spectrofluorimetry in multiple experiments confirmed these qualitative observations 
(Fig. 5B). OxyHb also inhibited albumin uptake in human proximal tubule HK-2 cells, which also 
express megalin/cubilin but have a markedly lower endocytic capacity than OK cells (Fig. 5C). 
 
Figure 5. Hemoglobin inhibits apical uptake of albumin by proximal tubule cells.  
A: filter-grown OK cells were preincubated for 30 min at 37°C with L-NAME (100 µM) where indicated and then 
exposed to 0.6 µM apically added Alexa Fluor 647-albumin in the presence or absence of 50 µM MetHb, CNMet-Hb, 
or OxyHb for 1 h at 37°C. After extensive washing, cells were fixed and processed for immunofluorescence to 
visualize cell-associated albumin. Representative fields are shown. Scale bar, 25 µm. B: cells incubated as above were 
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solubilized, and cell-associated albumin was quantified by spectrofluorimetry. Mean albumin uptake in control cells 
was set at 100 to facilitate comparison between experiments. The results from several independent experiments (means 
± SD of triplicate samples) are plotted, with each experiment represented by a different symbol. The mean uptake for 
a given condition is represented by the bar. C: filter-grown human HK-2 cells were incubated for 1 h at 37°C with 0.6 
µM Alexa Fluor 647-albumin in the presence or absence of 50 µM OxyHb. Cell-associated albumin was quantified 
as above, and the mean ± SD of three independent experiments each performed in triplicate is plotted. 
 
The insensitivity of albumin uptake to L-NAME and the equivalently robust inhibition we 
observed using Hb forms with different NO scavenging capabilities suggest that the effect of Hb 
on albumin uptake is independent of NO and independent of the heme reduction state. We 
hypothesized that Hb may be directly competing with albumin for binding to megalin/cubilin. Hb 
has been demonstrated using surface plasmon-reference analysis to bind to megalin and cubilin 
with affinities of 1.7 µM and 4.1 µM, respectively [60]. In comparison, albumin binds to OK apical 
membranes with a Kd of 0.3 µM [164]. 
Normalized data from multiple experiments demonstrated a dose-dependent effect of 
OxyHb on albumin uptake with an estimated half-maximal inhibitory concentration of ~5 µM (Fig. 
6). OxyHbS containing the SCD-causing mutation Glu7Val inhibited with a similar dose response. 
However, we still observed ~15% residual albumin uptake even when high concentrations of 
OxyHb (up to 250 µM) were added. 
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Figure 6. Dose response of hemoglobin and sickle cell hemoglobin S inhibition of albumin uptake. 
Triplicate filters of cells were preincubated with the indicated concentration of OxyHb or OxyHbS prior to addition 
of Alexa Fluor 647-albumin for 1 h and quantitation of albumin uptake. Cell-associated albumin in control untreated 
cells was normalized to 100 to enable combining data from multiple independent experiments, each represented by a 
distinct symbol. Based on this dose response, the half-maximal concentration at which OxyHb inhibits uptake of 
albumin is ~5 µM. 
 
Western blotting confirmed that prolonged exposure of human PT cells to Hb caused a 
dramatic elevation in heme oxygenase-1 as previously reported; however little if any upregulation 
was observed within 4 h of incubation (Fig. 7A). To confirm that the inhibitory effect of Hb on 
albumin endocytosis was not due to cellular toxicity, we preincubated cells with OxyHb for up to 
5 days with 10–50 µM OxyHb, then washed the cells and examined the effect on endocytosis of 
Alexa Fluor 647-albumin in the absence of competing Hb. As shown in Fig. 7B, preincubation 
with Hb had no effect on albumin uptake. Consistent with our previous results above, inclusion of 
10 µM OxyHb in the apical medium during the 1 h uptake period reduced albumin endocytosis by 
>60%. In contrast, when OxyHb was added to the basolateral medium of the Transwell filter 
supports, it had no effect on albumin uptake (not shown). 
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Figure 7. Hemoglobin acutely inhibits receptor-mediated endocytosis in proximal tubule cells. 
A: HK-2 cells were incubated with 50 µM OxyHb for 4 h or 3 days as indicated, then solubilized and blotted to detect 
heme oxygenase-1 (HO-1) and β-actin (as a loading control). Quantitation of HO-1 expression (avg ± range) relative 
to control and normalized to β-actin in two independent experiments is shown next to the blot. B: filter-grown OK 
cells were preincubated at 37°C with apically added OxyHb (10–50 µM) for 18 h to 5 days as indicated prior to 
extensive washout and subsequent addition of Alexa Fluor 647-albumin for 1 h at 37°C in the absence of OxyHb. As 
a positive control, OxyHb (10 µM) was included during the albumin uptake period; untreated cells incubated with 
Alexa Fluor 647-albumin were used as a negative control. Fluorescent cell-associated albumin was quantified by 
spectrofluorimetry. Data (means ± SD) from three independent experiments each performed in triplicate are shown. 
 
3.2.2  Albumin inhibits hemoglobin uptake by proximal tubule cells. 
Hb has previously been shown to be internalized by cells in the PT via a megalin-dependent 
pathway [60]. In those studies, addition of BSA did not inhibit Hb binding, suggesting that albumin 
and Hb may interact with distinct sites on megalin/cubilin. To examine this in OK cells, we 
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incubated OK cells with 1 µM apically added Alexa Fluor 568-OxyHb for 1 h, then fixed and 
imaged the cells. As shown in Fig. 8A, Hb was internalized into vesicular compartments similar 
to those observed with fluorescent albumin (Fig. 5A). As expected for a receptor-mediated event, 
uptake was abolished by inclusion of excess unlabeled Hb during the incubation period (Fig. 8A). 
We also observed significant inhibition of Hb uptake upon inclusion of 30 µM albumin (Fig. 8A). 
To test this further, we examined the dose dependence of albumin inhibition of Hb uptake using 
our spectrofluorimetry assay. In these experiments we found that 50 µM unlabeled Hb inhibited 
the uptake of fluorescently conjugated Hb by ~75% and 30 µM albumin inhibited Hb uptake by 
~50% (Fig. 8B). 
 
Figure 8. Albumin inhibits endocytosis of hemoglobin by OK cells. 
A: OK cells were incubated with apically added 2 µM Alexa Fluor 568-Hb in the presence or absence of 50 µM 
unlabeled OxyHb or 30 µM albumin for 1 h at 37°C, then fixed and processed for immunofluorescence. As a control 
to confirm that OxyHb fluorescence is not detected in our studies, cells were incubated for 1 h with 50 µM unlabeled 
OxyHb (right-hand panel) Scale bar, 25 µm. B: OK cells were incubated with apically added 2 µM Alexa Fluor 568-
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Hb in the presence or absence of the incubated concentrations of albumin or unlabeled Hb for 1 h at 37°C prior to 
quantitation of cell-associated Hb fluorescence. Data from two experiments performed in triplicate are shown. 
Background fluorescence in cells incubated only with 50 µM unlabeled OxyHb was <10% that of the control values. 
 
3.2.3  Haptoglobin inhibits Hb uptake by proximal tubule cells and restores albumin 
endocytosis. 
Hpt is a large (unfiltered) protein in serum that binds with very high affinity (estimated Kd 
> 10−12 M) to the dimer-dimer interface of Hb [153, 165, 166]. We found that 10 µM Hpt inhibited 
uptake of Alexa Fluor 568-OxyHb by OK cells (Fig. 9A). We used our spectrofluorimetry assay 
to confirm this quantitatively. However, because of the prohibitive cost of Hpt, we performed these 
assays with low concentrations of OxyHb (7.5 µM) and stoichiometric amounts of Hpt. As shown 
in Fig. 9B, addition of 7.5 µM OxyHb to OK cells inhibited the uptake of Alexa Fluor 647-albumin 
by ~30%. Preincubation of 7.5 µM OxyHb for 30 min with 7.5 µM Hpt restored albumin uptake 
to nearly control levels (Fig. 9B). Hpt also reversed the inhibitory effect of HbS on albumin uptake 
with comparable efficacy (not shown). Addition of 7.5 µM Hpt without Hb resulted in a minor but 
not statistically significant reduction in albumin uptake, suggesting that Hpt itself may weakly 
inhibit albumin uptake as well. 
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Figure 9. Haptoglobin inhibits hemoglobin uptake and restores albumin endocytosis by OK cells. 
A: OK cells were incubated with 2 µM Alexa Fluor 568-OxyHb for 1 h at 37°C in the presence or absence of 10 µM 
haptoglobin (Hpt), then washed, fixed, and processed for immunofluorescence to visualize cell-associated Hb. Scale 
bar, 25 µm. B: filter-grown OK cells were incubated with 40 µg/ml Alexa Fluor 647-albumin in the presence of OxyHb 
(7.5 µM) and/or 7.5 µM Hpt as indicated. After extensive washing, cells were solubilized and fluorescent cell-
associated albumin was quantified. Data (means ± SD) from two independent experiments each performed in triplicate 
are shown. 
 
3.2.4  Modeling the hemoglobin interaction site with megalin. 
As shown above, our results indicate that low concentrations of Hb (<10 µM) can impair 
albumin uptake. In addition, stoichiometric amounts of Hpt prevent this inhibition. The structure 
of the Hb-Hpt complex is known, involving two Hpt molecules and a Hb dimer [153]. Thus, it is 
reasonable to hypothesize that the binding site of Hb to megalin/cubilin may no longer be exposed 
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upon the formation of the Hb-Hpt complex. In addition, the competitive effect of albumin suggests 
that the binding sites used by albumin and Hb may share similar properties. Based on these 
premises we searched for Hb motifs that met the following conditions: 1) are solvent-exposed in 
the dimer Hb structure, 2) are involved in the Hb-Hpt interface, 3) share sequence and structural 
similarity to motifs in albumin, 4) share electrostatic surface similarities to motifs in albumin. 
The interaction of Hb and Hpt covers a large (2,954 Å2) surface with a number of Hb motifs 
involved [153]. The regions of Hb involved in the interface include the helices G and H in Hb α 
and the helices C, G, and H of Hb β [153]. As albumin and Hb are all-α-helical proteins, we used 
individual Hb α-helices as our search motif. 
The Hb helical fragments involved in Hpt binding were aligned to human albumin 
sequence to search for comparable albumin motifs. Portions of albumin showing sequence 
homology to the Hb sequences were inspected for similar secondary structure. Three regions of 
albumin with sequence homology and similar secondary structure were identified (Fig. 10). Based 
on these results we conclude that helices G and H in Hb may be involved in the interaction with 
megalin/cubilin. 
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Figure 10. Sequence and structure comparison of potential megalin/cubilin binding regions in hemoglobin 
and albumin. 
Hb helical fragments involved in Hpt binding were aligned to human albumin sequence to search for comparable 
albumin motifs (see materials and methods for details). Three sequences in albumin were identified that have sequence 
and structural similarity to Hb. Top: alignment of Hb α- and β-helix H to albumin residues 244–271. The sequence 
alignment is shown on top. Aligned sequences are shown in the structures of albumin and Hb αβ-dimer and indicated 
by a red box. Helical elements are shown in red (albumin, hemoglobin α) and salmon (hemoglobin β); Middle: 
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alignment of Hb α- and β-helix H to albumin residues 561–588. The sequence alignment is shown on top. Aligned 
sequences are shown in the structures of albumin and Hb αβ-dimer and indicated by a red box. Helical elements are 
shown in pink (albumin) red (hemoglobin α), and salmon (hemoglobin β) Bottom: alignment of Hb α- and β-helix G 
to albumin residues 87–105. The sequence alignment is shown on top. Aligned sequences are shown in the structures 
of albumin and Hb αβ-dimer and indicated by a blue box. Helical elements are shown in dark blue (albumin, 
hemoglobin α) and cyan (hemoglobin β). 
3.3 Discussion 
Our results demonstrate that binding of Hb to megalin/cubilin competes directly for the 
uptake of albumin by PT cells. We observed potent inhibition of albumin uptake by concentrations 
of Hb predicted to enter the tubule lumen in patients during hemolytic crisis. We hypothesize that 
competition for ligand binding by excess Hb in the tubule lumen, rather than cytotoxic responses 
to heme, are the cause of tubular proteinuria frequently observed in SCD patients. Additionally, 
loss of these ligands may contribute to impaired vitamin homeostasis in SCD patients. 
We found that 5 µM Hb and HbS inhibited albumin uptake by ~50%; however, we were 
unable to fully prevent uptake even at much higher concentrations of Hb. This suggests that 
albumin binds to multiple sites on megalin/cubilin, only some of which are inhibited by Hb. This 
is likely given that these receptors contain multiple ligand binding domains to engage a broad array 
of filtered ligands [159]. Additionally, non-receptor-mediated mechanisms may contribute to the 
small amount of residual albumin uptake at high Hb concentrations. 
Our data suggest that the interaction site for Hb with megalin/cubilin overlaps the Hpt 
binding site within the dimer-dimer interface. Based on this finding and on BLAST searches for 
regions of homology between albumin and Hb that map to this interface, we identified three 
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sequences in albumin as putative binding motifs for megalin/cubilin, due to their sequence and 
structure similarities with Hb domains that are involved in Hpt binding. 
A surprising finding is that whereas PT cells are highly sensitive to Hb, we did not observe 
any apparent toxicity in OK or HK-2 cells even after prolonged exposure to OxyHb. Control 
studies confirmed upregulation of heme oxygenase 1 in HK-2 cells exposed to OxyHb as 
previously reported [167]. However, preincubation of OK cells with 50 µM OxyHb for up to 5 
days did not impair subsequent albumin uptake. It is possible that other functions of our cells are 
compromised by exposure to Hb. 
Our findings have potential implications for our understanding the pathogenesis of SCD. 
Hb αβ-dimers in the plasma are readily filtered into the tubule lumen in the absence of glomerular 
injury and reach concentrations during hemolytic crisis that would significantly impair the 
reabsorption of albumin and other megalin/cubilin ligands. Thus, our finding may explain why a 
significant fraction of young SCD patients exhibit tubular proteinuria independent of glomerular 
damage [10, 12]. Prolonged exposure of PT cells to Hb is likely to overwhelm protective responses 
and lead to tubular injury that may initiate and/or contribute to the progression of CKD/end-stage 
renal disease in SCD patients. 
Our results suggest a possible explanation for why children with severe manifestations of 
SCD have abnormally low levels of 25(OH)D [17] and low bone mineral density [168]. Defective 
uptake of filtered ligands by megalin/cubilin in the PT is known to affect serum vitamin levels. 
This is especially evident in the case of vitamin D3, which is taken up by megalin/cubilin in its 
inactive, insoluble form [25(OH)D] bound to DBP, converted to the active 1,25(OH)2D form, and 
released from the basolateral surface of PT cells into the bloodstream [169]. For example, patients 
with Dent disease, caused by mutations in a PT hydrogen-chloride antiporter that plays a role in 
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apical endocytosis, have low levels of vitamin D3 and frequently develop osteomalacia and 
hypophosphatemic rickets [129]. Cubilin-deficient dogs also have lower serum levels of mono- 
and dihydroxylated vitamin D3 metabolites [128]. Although we did not test whether Hb competes 
for uptake of DBP, it is notable that DBP is highly homologous to albumin [170]. Our studies 
provide a potential mechanism to explain the early steps in the development of kidney disease and 
suggest the possibility that selectively targeting the interaction of Hb with megalin/cubilin may 
have therapeutic value beyond simply preserving PT function in SCD patients. 
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4.0 Hemoglobin Alters Vitamin Carrier Uptake and Mitochondrial Dynamics in Proximal 
Tubule Cells: Implications for Vitamin D Metabolism in Sickle Cell Disease Patients 
4.1 Introduction 
SCD is one of the most prevalent monogenic disorders and is caused by autosomal 
recessive inheritance of pathogenic mutations in the β-globin subunit of Hb. These mutations 
increase Hb polymerization in RBCs, forcing them into a sickled shape, and lead to increased 
vascular blockage and hemolytic crisis in SCD patients [38]. In recent years, therapeutic advances 
have significantly extended SCD patient lifespan, causing a rise in the prevalence of severe 
comorbidities, including SCN. SCN currently accounts for up to 18% of SCD patient mortality 
and is thought to arise in consequence of both recurring hemolytic crisis in the hypoxic renal 
medulla and increased exposure to cell-free Hb released in RBC hemolysis [6].  
Compared to healthy individuals, SCD patients chronically have approximately 10 times 
higher concentrations of circulating cell-free Hb, and serum concentrations can reach up to 1 g/dl 
(620 µM) during times of hemolytic crisis [158]. Hb circulates primarily as dimers (~32 kDa), 
which can escape the glomerular barrier and enter the PT lumen. Reabsorption of filtered proteins 
by PT epithelial cells is accomplished through apical endocytosis mediated by megalin and cubilin 
receptors [96]. Megalin and cubilin each possess multiple interaction sites that enable the binding 
and internalization of numerous filtered proteins, including Hb [60, 159]. Incomplete reabsorption 
can cause tubular proteinuria, defined as urinary loss of proteins normally reabsorbed by the PT. 
Importantly, many young SCD patients develop tubular proteinuria [10-12], suggesting that PT 
dysfunction occurs early in the progression of kidney disease.  
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Prolonged PT dysfunction and tubular proteinuria have been linked to kidney inflammation 
and fibrosis, which can eventually lead to glomerular dysfunction, frank proteinuria, and renal 
failure [13, 14]. Additionally, PT dysfunction can prevent normal uptake of vitamin carrier 
proteins that bind to megalin and cubilin, including DBP and RBP, and failure to reclaim these 
carrier proteins can lead to vitamin deficiencies [129, 159, 171, 172]. This is particularly true for 
vitamin D, as the PT is the primary site for vitamin D reclamation and activation [16]. There is a 
high prevalence of vitamin D deficiency in SCD patients [17, 18], although the contribution of PT 
dysfunction is unknown.  
We previously reported that excess Hb can inhibit albumin endocytic uptake by PT cells 
[173]. Because albumin and DBP have similar secondary structures, we hypothesized that Hb may 
also inhibit DBP uptake by PT cells. Additionally, Hb-induced cytotoxicity in PT cells could affect 
vitamin D metabolism, as oxidative stress has been linked to altered PT vitamin D hydroxylase 
expression and activity [174-176]. Reduced DBP uptake and impaired vitamin D metabolism in 
the PT could play a significant role in the development of vitamin D deficiency in SCD patients. 
Thus, we set out to assess how exposure to cell-free Hb affects the uptake of vitamin carriers DBP 
and RBP, and vitamin D hydroxylase expression in PT cells. We found that Hb significantly 
inhibits DBP uptake, similarly to what we reported for albumin. However, uptake of RBP was 
considerably less sensitive to Hb, suggesting that Hb binding competition is selective for a subset 
of megalin/cubilin ligands. Additionally, we observed that prolonged exposure to Hb led to 
increased oxidative stress at the mitochondrial level in PT cells and to discordant changes in 
CYP27B1 mRNA and protein levels. Together, our data suggests that increased cell-free Hb levels 
in SCD patients may impair vitamin D reclamation and activation by PT cells, which could 
contribute to vitamin D deficiency commonly observed in patients. 
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4.2 Results 
4.2.1  Hemoglobin inhibits DBP uptake similarly to previously reported inhibition of 
albumin uptake in proximal tubule cells 
To assess any inhibitory effect of Hb on DBP uptake, we incubated polarized, filter-grown 
OK cells with 25 nM Alexa Fluor 647-labeled DBP (comparable to the estimated tubular 
concentration) in the presence or absence of unlabeled oxyHb at concentrations estimated to enter 
the kidney tubule lumen chronically (0.6 µM) or during hemolytic crisis (≤20 µM) in SCD patients. 
Cells were incubated under these conditions for 1 h to allow for significant endocytic uptake, 
washed extensively, solubilized, and cell-associated DBP was quantified by spectrofluorimetry. 
DBP uptake was significantly inhibited in a dose dependent manner by all concentrations of Hb 
tested (Fig. 11A). Half-maximal inhibition of DBP was observed at ~0.8 µM Hb, close to the 
estimated chronic tubular concentration in SCD. At the highest Hb concentration tested (20 µM) 
DBP uptake was inhibited by 87% (Fig. 11A). OxyHb also significantly inhibited DBP uptake in 
a porcine PT cell line (LLC-PK1) that expresses megalin and cubilin receptors but has substantially 
lower endocytic capacity in comparison to OK cells (Fig. 11B).  
To further elucidate whether reduced DBP uptake is due to competitive inhibition by Hb, 
we differentially labeled Hb with Alexa Fluor 488 and measured DBP and Hb uptake 
simultaneously in PT cells. These dual fluorescence assays were scaled down to a 96-well plate 
format to enable incubation with high concentrations of Alexa Fluor 488-Hb. After incubation with 
fluorescently-labeled proteins for 2 h, cells were solubilized, and cell-associated fluorescence 
quantified. In agreement with our hypothesis, DBP uptake decreased while Hb uptake increased 
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with increasing concentrations of Hb (Fig. 11C). Of note, the estimated half-maximal inhibition of 
DBP in these experiments (~0.9 µM Hb) is similar to that observed in cells grown on filters.  
 
Figure 11. Hb inhibits DBP uptake in proximal tubule cells via direct competition. 
A: Filter-grown OK cells were incubated with 25 nM apically-added Alexa Fluor 647-DBP in the presence of a range 
of oxyHb concentrations (0-20 µM) for 1 h at 37°C. Cells were then solubilized, and cell-associated DBP was 
quantified by spectrofluorimetry. Data from five experiments done in duplicate are plotted, with each experiment 
represented by a different symbol. B: Filter-grown LLC-PK1 cells were incubated with 0.5 µM Alexa Fluor 647-DBP 
in the presence or absence of 20 µM oxyHb and cell-associated DBP was quantified as in (A). Data from three 
experiments (mean ± SD and individual points) performed in duplicate were plotted. C: OK cells grown in a 96-well 
plate were incubated with 25 nM Alexa Fluor 647-DBP and a range of Alexa Fluor-488 Hb concentrations (0-20 µM) 
for 2 h at 37°C. Cell-associated DBP and Hb fluorescence were quantified by spectrofluorimetry. Data (mean ± SD) 
from four experiments performed in sextuplicate are shown. Graphed uptake values were normalized by dividing each 
point by their respective experimental mean. **p≤0.01, ****p≤0.0001 by one-way ANCOVA Dunnett’s multiple 
comparisons (A), two sample t-test (B), or two-way ANOVA Dunnett’s multiple comparisons (C).  
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Because DBP and albumin are comparable in size and secondary structure, we posited that 
Hb would compete for PT cell uptake with both proteins similarly. To test this, we measured uptake 
of 0.6 µM Alexa Fluor 647-albumin and Alexa Fluor 488-Hb in the same manner as described 
above. As expected, Hb inhibits albumin uptake in a very similar dose-dependent manner to DBP 
(Appendix B Fig. 20). Interestingly, the estimated half-maximal inhibition of albumin (~0.6 µM 
Hb) was similar to that observed for DBP (~0.8-0.9 µM Hb). We also observed equivalent PT cell 
Hb uptake after incubation with albumin and DBP (Fig. 11C and Appendix B Fig. 20, gray line). 
Together, these data suggest that Hb similarly competes with predicted tubular concentrations of 
albumin and DBP. 
4.2.2  Hemoglobin marginally inhibits RBP uptake by proximal tubule cells. 
Because we found Hb similarly inhibits uptake of albumin and DBP, we hypothesized Hb 
binding inhibition may be selective for proteins highly alpha helical in structure. To test this, we 
measured the uptake of RBP, a smaller filtrate protein (~21 kDa) comprised primarily of β-sheets, 
in the presence or absence of oxyHb at the same concentrations as above. While oxyHb 
significantly inhibited uptake of 0.1 µM Alexa Fluor 647-RBP in both OK cells and LLC-PK1 
cells (Fig. 12), the effect size of this inhibition was smaller in comparison to observed albumin 
and DBP inhibition. In OK cells, RBP uptake was inhibited by 27% at the highest Hb concentration 
tested (20 µM) (Fig. 12A), which is much less than the observed ~87-93% inhibition of 
albumin/DBP uptake. This suggests that Hb does not compete with RBP for receptor binding in 
the same manner it does with albumin and DBP. However, it is important to note that Hb inhibition 
of RBP, albeit marginal, was present in PT cells.  
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Figure 12. Hb inhibits RBP uptake by proximal tubule cells. 
A: Filter-grown OK cells were incubated with 0.1 µM apically-added Alexa Fluor 647-RBP in the presence of a range 
of Hb concentrations (0-20 µM) and cell-associated RBP was quantified as above. Data from four experiments done 
in duplicate are plotted, with each experiment represented by a different symbol. Graphed uptake values were 
normalized by dividing each point by their respective experimental mean. B: Filter-grown LLC-PK1 cells were 
incubated with 0.5 µM RBP in the presence or absence of 20 µM Hb and cell-associated RBP was quantified. Data 
(mean ± SD and individual points) from three experiments performed in duplicate are plotted. *p≤0.05, ****p≤0.0001 
by one-way ANCOVA Dunnett’s multiple comparisons (A) or two sample t-test (B). 
 
4.2.3  Chronic exposure to hemoglobin increases mitochondrial oxidative stress in proximal 
tubule cells and alters vitamin D hydroxylase expression 
After observing that Hb outcompetes DBP for PT cell uptake we began to consider the 
effects of increased concentrations of Hb entering PT cells. Hb exposure can lead to increased 
oxidative stress through increased ROS production and lipid peroxidation [36]. These same forms 
of oxidative stress have been shown to altered hydroxylase expression and activity [175, 176], 
suggesting Hb-induced oxidative stress could limit vitamin D metabolism in the PT through 
manipulation of vitamin D hydroxylases CYP27B1 and CYP24A1. As vitamin D hydroxylases 
are localized within the mitochondria of PT cells, we first set out to assess oxidative stress at the 
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mitochondrial level in our culture model. To do this, we measured the enzymatic activity of 
aconitase, an enzyme in the citric acid cycle that converts citrate to isocitrate and is localized 
primarily to mitochondria. Oxidation of the iron cluster within aconitase’s active site results in 
ablation of the enzyme’s catalytic activity. As a result, reduced aconitase activity is a sensitive 
indicator of mitochondrial-specific oxidative stress [177]. Filter-grown PT cells were incubated in 
the presence or absence of Hb (oxyHb and metHb) at different concentrations for 24-72 h. Cells 
were then washed, lysed, and equal volumes of lysate were incubated with substrate (citrate) for 1 
h. Aconitase activity was then quantified by colorimetric development of produced isocitrate and 
normalized to sample total protein. Exposure to metHb alone led to a significant decrease in 
aconitase activity in OK cells, suggesting increased oxidative stress (Fig. 13). Although metHb is 
reportedly more toxic [32, 36], it was surprising that chronic oxyHb exposure did not also affect 
mitochondrial oxidative stress. LLC-PK1 cells exhibited similar trends in oxidative stress to OK 
cells (Appendix B Fig. 21), but to a lesser magnitude. This is likely due to reduce Hb endocytic 
uptake. 
 
Figure 13. Chronic metHb, but not oxyHb, exposure decreases aconitase activity in proximal tubule cells. 
Filter-grown OK cells were incubated with metHb (A) or oxyHb (B) for 24-72 h at the concentrations indicated. Cells 
were then washed, lysed, and equal lysate volumes were incubated with aconitase substrate for 1 h. Colorimetric 
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measurement of isocitrate production was used to quantify sample aconitase activity and normalized to total protein. 
Data (mean ± SD and individual points) from 3-4 experiments are plotted. Graphed values were normalized by 
dividing each point by their respective experimental mean. **p≤0.01, ***p≤0.001 by one-way ANCOVA Dunnett’s 
multiple comparisons.  
 
After confirming increased oxidative stress in our PT cell culture model, we next set out to 
measure any effects this had on vitamin D hydroxylase expression. To do so, we treated filter-
grown OK cells chronically (72 h) with either high or low concentrations of oxyHb or metHb as 
indicated. Cells were then lysed, and total RNA and protein were collected. Quantitative PCR 
(qPCR) and western blotting were performed to measure CYP24A1 and CYP27B1 mRNA and 
protein expression, respectively. Sample mRNA expression was normalized to ACTB mRNA 
levels, while protein expression was normalized to total loaded protein. Interestingly, we observed 
a selective increase in CYP27B1 transcript expression after exposure to both metHb and oxyHb 
(Fig. 14). This increase in transcript level was not mirrored by increased CYP27B1 protein as both 
vitamin D hydroxylase proteins’ expression were unchanged with Hb treatment (Fig. 14, C and 
D).  
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Figure 14. Prolonged Hb exposure selectively increases CYP27B1 transcript levels in proximal tubule cells. 
Filter-grown OK cells were incubated with oxyHb or metHb for 72 h at concentrations indicated. Cells were then 
washed, lysed, and total RNA and protein were collected. Expressional changes of CYP24A1 and CYP27B1 transcripts 
(A and B, respectively) were quantified by qPCR and normalized to ACTB transcript levels. Changes in protein 
expression of  CYP24A1 and CYP27B1 (C and D, respectively) were quantified via western blotting of equal total 
protein. Representative western blot data for CYP24A1 (E) and CYP27B1 (F) expression are shown. Relative fold 
change (RFC) in treatment conditions compared to an untreated control (not shown) from five experiments are plotted 
(mean ± SD and individual points). *p≤0.05, **p≤0.01, by one-sample t-test.  
 
Because oxidative damage to proteins can affect degradation rates [178], we hypothesized 
that the observed disconnect between increased mRNA and unchanged protein levels of CYP27B1 
may be due to increased protein degradation. However, cycloheximide chase experiments 
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suggested that CYP24A1 and CYP27B1 half-lives are long (>8 h) and not appreciably altered by 
Hb exposure (data not shown).  
4.3 Discussion 
Our results demonstrate that Hb at concentrations estimated to be present within the kidney 
tubule lumen of SCD patients profoundly inhibits DBP uptake by PT cells. The concentration of 
Hb that half-maximally inhibits DBP uptake is close to its estimated tubular concentration in 
patients. Thus, Hb competition for DBP uptake may result in chronic loss of filtered DBP into the 
urine, which could contribute to the development of vitamin D deficiency commonly observed in 
SCD. Additionally, impaired DBP uptake by the PT may hamper the effectiveness of vitamin D 
supplementation. Indeed, vitamin D supplementation is more difficult in SCD patients compared 
with otherwise healthy, vitamin D-deficient individuals. Because of this, SCD patients generally 
need a higher dose to reach sufficiency  [179, 180].  
In addition to inhibiting DBP uptake, we found that prolonged metHb exposure led to 
increased mitochondrial-associated oxidative stress in PT cells. Because oxidative stress has been 
associated with changes in vitamin D hydroxylase expression and function [174-176], we next 
assessed CYP24A1 and CYP27B1 expression in PT cells after prolonged Hb exposure. 
Interestingly, both metHb and oxyHb exposure led to a differential increase in CYP27B1 mRNA 
expression with unchanged protein expression. Upon finding this discordant change in CYP27B1 
expression with Hb exposure, we speculated CYP27B1 protein may be degrading at an enhanced 
rate, which could balance any increased transcription and translation to result in the appearance of 
unchanged protein levels. However, we were unable to measure an appreciable difference in 
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protein degradation with Hb treatment.  This suggests that the observed discordant changes in 
CYP27B1 mRNA and protein levels could be caused by alteration of translational or post-
translational regulation rather than protein degradation. Additionally, the effect on CYP27B1 
mRNA expression may not directly depend on oxidation levels as oxyHb did not increase 
mitochondrial oxidative stress, but increased CYP27B1 expression similarly to metHb. 
An important extension of our results would be to measure the effects of prolonged 
exposure to Hb on the enzymatic activity of CYP27B1 and CYP24A1, which could also affect 
vitamin D metabolism in PT cells. Interestingly, HO-1 induction can lead to degradation of heme 
groups in the active site of CYP family proteins, causing decreased activity [174, 181], and a 
previous study reported decreased vitamin D hydroxylase activity under conditions of oxidative 
stress [175]. Consistent with this possibility, we have reported increased HO-1 expression in 
human PT cells after prolonged exposure to Hb [173]. Further studies are needed to truly assess 
the impact of prolonged Hb exposure on PT vitamin D metabolism, including evaluation of vitamin 
D metabolite production in both in vitro and in vivo models of SCD. Nevertheless, we have 
provided the first implications that SCD-related PT dysfunction may contribute to vitamin D 
deficiency to our knowledge. This suggests the PT as a crucial target for therapeutic intervention 
to maintain vitamin D levels in SCD patients. 
Our studies indicate that impeding the interaction of Hb with megalin/cubilin receptors 
may be a useful therapeutic approach in the prevention of both vitamin D deficiency and tubular 
proteinuria in SCD patients. Hb differentially inhibited the uptake of normally filtered proteins, 
suggesting specificity in Hb-receptor binding. We observed similar degrees of Hb inhibition on 
albumin and DBP uptake, suggesting that Hb, albumin, and DBP bind to common sites in megalin 
and cubilin receptors. RBP uptake was inhibited by Hb to a lesser degree. As the secondary 
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structure of RBP is unlike that of Hb, albumin, and DBP it likely binds to different sites to 
megalin/cubilin receptors. The difference in competition could also be related to receptor-specific 
binding as Hb [60], albumin [98, 182], and DBP [128] are reported to bind to both megalin and 
cubilin, and RBP [183] is only reported to bind to megalin. However, it should be noted that 
inhibition of all tested proteins by Hb remained incomplete even at high concentrations of Hb. 
This suggests that there may be some difference between binding sites specific to Hb, albumin, 
and DBP. There may also be some endocytosis via nonspecific binding or fluid phase uptake in 
PT cells. Understanding the molecular basis of Hb competition would help identify therapeutic 
compounds that selectively target the interaction of Hb with megalin/cubilin receptors. Further, 
recognizing differences in Hb competition with specific proteins may provide useful information 
for the selection of early biomarkers of tubular proteinuria in SCD patients. Urinary excretion of 
RBP has been previously used in the diagnosis of tubular proteinuria in the pediatric SCD 
population [12]. However, our data suggest that RBP may not be an ideal biomarker of tubular 
proteinuria in SCD patients, as its uptake is not inhibited as profoundly as other proteins such as 
DBP. Therefore, we propose measurement of urinary DBP excretion as a biomarker since it may 
allow for diagnosis of tubular proteinuria earlier and/or with greater sensitivity. Future studies 
assessing patterns of urinary protein excretion early in life may help to better understand how to 
best characterize the progression of tubular proteinuria and its relation to kidney disease in SCD 
patients. 
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4.4  Future Directions 
Further studies, including additional assessment of vitamin D hydroxylase enzyme activity 
after Hb exposure, are needed to determine a link between our observed change in CYP27B1 
mRNA expression and alteration of vitamin D metabolism. We have set up a collaboration with 
Dr. Thomas Nolin at the University of Pittsburgh School of Pharmacy, to measure vitamin D 
metabolite production. Dr. Nolin has previously measured vitamin D metabolites in human serum 
using ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-
MS/MS) [184]. We plan to expand this technique to measure vitamin D metabolites in our LLC-
PK1 cell model as these cells have been previously reported to metabolize 25(OH)D to 
1,25(OH)2D and 24,25(OH)2D [185-187]. UHPLC-MS/MS can measure all metabolites pertinent 
to this study [25(OH)D, 1,25(OH)2D, 24,25(OH)2D] and has the sensitivity to read levels as low 
as 5 ng/ml 25(OH)D and 10 pg/ml 1,25(OH)2D. We have treated LLC-PK1 cells with 25(OH)D 
in various culture conditions, including free or DBP-bound incubation in the presence or absence 
of Hb, and have collected cell lysates and culture medium for analysis. Dr. Nolin is currently 
improving his vitamin D metabolite assay, and, upon proper optimization, we will run these 
samples to assess any changes in metabolism. 
Our measurement of vitamin D metabolites will also be extended beyond in vitro cell 
culture to assess vitamin D status in the Townes SCD mouse model. We are currently collecting 
serum from SCD mice with matched controls to assess any differences in circulating vitamin D 
metabolites. There are some caveats of measuring mouse serum which may make interpretation of 
these data difficult. This includes the amount of serum needed to measure vitamin D metabolites. 
Dr. Nolin’s assay requires a minimum of 0.5 mL serum volume, which necessitates complete 
exsanguination of the experimental mice. This means we will not be able to conduct repeated 
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measures and any variation in sample collection may have a large effect on differences in vitamin 
D metabolites collected. Additionally, pushing the metabolite assay to its lower volume limit may 
hinder the discernment of subtle changes in vitamin D metabolites. Nevertheless, these data could 
help to demonstrate possible clinical relevance of our in vitro studies as it would extend our 
profiling of SCD-related vitamin D deficiency beyond a single cell environment. 
If either in vitro or in vivo models provide promising results, we would likely consider 
assessment of serum vitamin D metabolite status in humans. Measuring vitamin D metabolite 
levels in humans would be more complicated by environmental confounders, such as sun exposure 
and dietary intake of vitamin D. However, assessing vitamin D metabolism in a human SCD cohort 
should be possible if recruitment accounted for these environmental confounders as well as 
differences in disease state, such as frequency of hemolytic crises and Hb serum concentration at 
time of sample collection.  
In addition to assessment of vitamin D metabolism, we may use our PT cell model to screen 
for therapeutic compounds. We have developed a scalable, dual fluorescent screen that measures 
simultaneous PT cell uptake of albumin/DBP and Hb. This assay could be used to find compounds 
that selectively inhibit Hb interaction with megalin and cubilin. Because we have observed 
differential binding inhibition by Hb on the uptake of albumin and DBP vs. RBP, structural 
analysis looking at similarities and differences between these proteins may help to refine 
compounds to use in a targeted drug screen. It will be difficult to find compounds that only inhibit 
Hb uptake, as Hb likely contains multiple low affinity binding sites similar to other filtered 
proteins. However, global inhibition of PT endocytic uptake may still be useful in preventing 
uptake of large amounts of Hb filtered during hemolytic crisis, which could help to preserve kidney 
function in patients. 
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5.0  Vitamin D Alters Protein Endocytosis by Proximal Tubule Cells 
5.1 Introduction 
Hormonally active vitamin D [1,25(OH)2D] regulates a multitude of cellular processes 
through binding to VDR. Regulation by 1,25(OH)2D-VDR is cell-type specific and primarily 
mediates changes in gene transcription to alter biological activity [119]. 1,25(OH)2D-VDR is 
involved in regulating calcium homeostasis, cellular proliferation and differentiation, hormone 
secretion, and immune function [123]. Because of its involvement in a variety of cellular processes, 
sustaining appropriate levels of active vitamin D is critical. 
PT cells are among the few cell types that express CYP27B1, which converts 25(OH)D to 
1,25(OH)2D and are generally considered the primary site for vitamin D activation in the body 
[16]. PT cells also express VDR, and 1,25(OH)2D-mediated regulation of several genes in in these 
cells has been reported [125, 131]. Overall, the transcriptional regulation in PT cells functions as 
a negative feedback loop to suppress vitamin D activation once sufficient levels are available. For 
example, 1,25(OH)2D-VDR signaling can reduce PT expression of CYP27B1 and concomitantly 
increase levels of CYP24A1, a hydroxylase involved in vitamin D degradation, to limit total 
1,25(OH)2D levels [123].  
1,25(OH)2D is also reported to regulate PT cell expression of multiligand receptors megalin 
and cubilin [132, 133]. Megalin and cubilin bind to many proteins in the kidney ultrafiltrate, 
including vitamin D carrier proteins albumin and DBP, and are critical for robust protein 
reabsorption [159]. Changes in protein uptake driven by vitamin D regulation could have 
implications for kidney function and health. Incomplete reabsorption of protein by the PT can 
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cause urinary excretion of unabsorbed protein, termed tubular proteinuria. Tubular proteinuria has 
been linked to deterioration of kidney function and progression of disease [13, 14]. Additionally, 
incomplete vitamin carrier reclamation could affect vitamin status. Reported 1,25(OH)2D-
mediated changes in receptor expression are discordant as expression of megalin increases and 
cubilin decreases [132, 133]. Thus, it is difficult to postulate the effect of 1,25(OH)2D regulation 
on endocytic uptake. 
Because PT cell protein reabsorption plays a critical role in the maintenance of vitamin 
homeostasis as well as a protein-free urine, it is important to understand any correlation between 
1,25(OH)2D regulation of megalin and cubilin expression and endocytic uptake. Therefore, we set 
out to assess PT cell uptake of several megalin/cubilin ligands under conditions simulating 
1,25(OH)2D supplementation. We measured albumin, DBP, and RBP uptake as well as changes in 
megalin and cubilin mRNA and protein expression in two PT cell lines treated with 1,25(OH)2D. 
We observed increased RBP uptake in both cell lines upon exposure to 1,25(OH)2D. However, 
only one of the two tested cell lines (LLC-PK1) exhibited 1,25(OH)2D-driven changes in receptor 
expression. This cell line also exhibited increased DBP uptake after 1,25(OH)2D exposure. While 
the observed changes in endocytosis were different between cell lines and of relatively small 
magnitude, our results suggest that active vitamin D status and signaling may influence protein 
reabsorption by the PT. 
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5.2 Results 
5.2.1  1,25(OH)2D supplementation increases RBP endocytic uptake in proximal tubule 
cells 
To investigate the effect of 1,25(OH)2D supplementation on endocytic capacity, we 
conducted our experiments in opossum OK and porcine LLC-PK1 cells, two PT cell lines that are 
commonly used to study endocytosis and vitamin D signaling/metabolism. Polarized, filter-grown 
PT cells were cultured in the presence or absence of 1,25(OH)2D for 24 h. After exposure to 
1,25(OH)2D, OK cells were incubated with 0.6 µM Alexa Fluor 647-albumin, 0.1 µM Alexa Fluor 
647-DBP, or 0.1 µM Alexa Fluor 647-RBP for 1 h at 37°C. Cells were then washed, solubilized, 
and cell-associated fluorescent protein was quantified via spectrofluorimetry. Experiments using 
LLC-PK1 cells were conducted in the same manner, except concentrations of DBP and RBP were 
increased to 0.5 µM to increase the sensitivity of our uptake assay as LLC-PK1 cells have markedly 
lower endocytic capacity compared with OK cells. Treatment with 1,25(OH)2D increased RBP 
uptake in both OK and LLC-PK1 cells (Fig. 15 A and B). While the effect size was small (1.2-fold 
in OK cells and 1.5-fold in LLC-PK1 cells), this increase in uptake was significant in OK cells and 
congruent between both cell lines. Exposure to 1,25(OH)2D also led to apparently increased DBP 
uptake in LLC-PK1 cells (Fig. 15 C and D), but no effect on albumin uptake was observed (Fig. 
15 E and F). This was surprising as albumin and DBP likely bind to megalin and cubilin similarly 
since they have comparable secondary structures. To add to the complexity of this observation, the 
change in DBP uptake after 1,25(OH)2D exposure appeared to be biphasic, with 100 nM treatment 
causing the greatest increase in uptake (Fig. 15C).  
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Figure 15. Changes in 1,25(OH)2D treatment alter DBP and RBP uptake in in proximal tubule cells. 
Filter-grown proximal tubule cells were incubated with 1,25(OH)2D for 24 h at concentrations indicated. After 
treatment, cells were incubated with apically added Alexa Fluor 647-RBP (A and B), Alexa Fluor 647-DBP (C and 
D), or Alexa Fluor 647-albumin (E and F) for 1 h at 37°C. Cells were then solubilized, and cell-associated fluorescence 
was quantified by spectrofluorimetry. While 0.6 µM albumin was used to measure both LLC-PK1 (E) and OK (F) cell 
uptake, concentrations of RBP and DBP were different between cell lines: 0.5 µM RBP (A) and 0.5 µM DBP (C) in 
LLC-PK1 cells vs. 0.1 µM RBP (B) and 0.1 µM DBP (D) in OK cells. Data (mean ± SD and individual points) from 
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4-5 experiments done in triplicate are plotted. Graphed uptake values were normalized by dividing each point by their 
respective experimental mean. **p≤0.01, ***p≤0.001 by one-way ANCOVA Dunnett’s multiple comparisons. 
 
5.2.2  1,25(OH)2D regulation of megalin and cubilin receptor expression varies in proximal 
tubule cell lines 
While both cell lines are known to express megalin, cubilin, and VDR, 1,25(OH)2D-VDR 
regulation of megalin and cubilin expression has not been reported. Thus, we set out to measure 
megalin and cubilin expression after 1,25(OH)2D treatment to see if the observed changes in 
endocytosis could be correlated to changes in megalin/cubilin expression. Filter-grown PT cells 
were treated with the same concentrations of 1,25(OH)2D for 24 h as above. Cells were then were 
washed, lysed, and total RNA and protein collected and quantified. Quantitative PCR (qPCR) and 
western blotting were performed to analyze LRP2/megalin and CUBN/cubilin mRNA and protein 
expression, respectively. We observed a significant decrease in cubilin, but not megalin, 
expression with 1,25(OH)2D treatment in LLC-PK1 cells (Fig. 16).  
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Figure 16. Cubilin expression is significantly downregulated by 1,25(OH)2D in LLC-PK1 cells. 
Filter-grown LLC-PK1 cells were incubated with 1,25(OH)2D for 24 h at concentrations indicated. Cells were then 
washed, lysed, and total RNA and protein were collected. Expressional changes of LRP2 and CUBN transcripts (A 
and B, respectively) were quantified by qPCR and normalized to ACTB transcript levels. Changes in protein expression 
of  megalin and cubilin (C and D, respectively) were quantified via western blotting of equivalent loaded protein. 
Relative fold change (RFC) in treatment conditions compared to an untreated control (not shown) from three 
experiments are plotted (mean ± SD and individual points). Representative western blot data for megalin and cubilin 
expression are shown (E). *p≤0.05, **p≤0.01, by one-sample t-test. 
 
Surprisingly, OK cells did not exhibit a significant change in either megalin or cubilin 
expression with 1,25(OH)2D exposure (Fig. 17). However, we observed increased CYP24A1 
mRNA expression after treatment with 1,25(OH)2D in both cell lines (Fig. 22 in Appendix B), 
verifying that VDR signaling occurred at concentrations of 1,25(OH)2D tested. Together, our data 
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suggest that 1,25(OH)2D regulation of megalin and cubilin receptors is cell-line dependent and 
possibly species-specific. 
 
 
Figure 17. Megalin and cubilin expression is not regulated by 1,25(OH)2D in OK cells. 
Filter-grown OK cells were incubated with 1,25(OH)2D for 24 h at concentrations indicated. Cells were then washed, 
lysed, and total RNA and protein were collected. Expressional changes of LRP2 and CUBN transcripts (A and B, 
respectively) were quantified by qPCR and normalized to ACTB transcript levels. Changes in protein expression of 
megalin and cubilin (C and D, respectively) were quantified via western blotting of equivalent loaded protein. Relative 
fold change (RFC) in treatment conditions compared to an untreated control (not shown) from three experiments are 
plotted (mean ± SD and individual points). Representative western blot data for megalin and cubilin expression are 
shown (E).  
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5.3 Discussion 
Although 1,25(OH)2D supplementation has been reported to alter both megalin and cubilin 
expression previously [132, 133], we observed no regulation of megalin and decreased cubilin 
expression only in LLC-PK1 cells after 24 h of supplementation. Our inability to replicate changes 
in megalin expression in either cell line could be due to cell culture model differences. As 
1,25(OH)2D is known to regulate cell differentiation, the previous report of increased megalin 
expression with 1,25(OH)2D exposure conducted under static conditions [132] may be an effect of 
increased PT cell differentiation rather than direct VDR regulation of megalin. We may have 
missed this change with supplementation in our cells as they were cultured under fluid shear stress 
prior to 1,25(OH)2D supplementation, which we have demonstrated to increase PT cell 
differentiation and metabolic function [150, 188]. Conversely, we expect observed differences in 
1,25(OH)2D effects on cubilin expression between LLC-PK1 and OK cells to be species specific. 
While LLC-PK1 cells are derived from porcine origin and have been demonstrated to metabolize 
vitamin D similarly to humans, OK cells reportedly metabolize vitamin D differently. They have 
not been observed to produce 1,25(OH)2D and possess an evolutionary modification in CYP24A1 
that leads to alternative metabolite production [186, 189, 190]. This deviation in vitamin D 
metabolism may imply divergence in 1,25(OH)2D-VDR regulation as well. However, we found 
that 1,25(OH)2D treatment created a dramatic increase in CYP24A1 expression, suggesting that 
both LLC-PK1 and OK cells can respond to 1,25(OH)2D.  
Despite conflicting effects of 1,25(OH)2D on receptor expression, both OK and LLC-PK1 
cells had increased RBP uptake with 1,25(OH)2D treatment. It is difficult to understand how RBP 
uptake is increased in OK cells as there was no change in total megalin or cubilin expression with 
1,25(OH)2D treatment. However, 1,25(OH)2D treatment could possibly alter apical surface 
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expression of megalin/cubilin receptors, which may change endocytic dynamics. In fact, cubilin 
relies on another protein amnionless for trafficking to the apical surface of cells [105]. Because of 
this, it may be of interest to assess amnionless expression after 1,25(OH)2D treatment. 
Additionally, studies evaluating megalin and cubilin receptor localization after 1,25(OH)2D 
exposure are needed to determine any significant differences in apical surface expression. A 
change in nonspecific endocytosis or other possible RBP receptors expression may also explain 
increased RBP uptake in OK cells. Indeed, we have observed expression of the STRA6 receptor 
in OK cells [191], which can bind to RBP. STRA6 has only been reported to bind rather than 
internalize RBP and its localization in PT cells is not characterized, making it unclear if 
1,25(OH)2D regulation of STRA6 could cause the observed increase in cell-associated RBP. 
While we found no change in receptor expression in OK cells treated with 1,25(OH)2D, 
LLC-PK1 cells responded to treatment with a decrease in cubilin expression. We believe that this 
decreased cubilin expression is likely responsible for the observed increase in RBP uptake in LLC-
PK1 cells. Cubilin relies on interaction with other membrane proteins, such as megalin, for cell 
surface localization as it does not contain a membrane tether [159, 192]. While interaction between 
megalin and cubilin at the cell surface is not thought to alter either receptor’s binding specificity, 
we hypothesize that decreased megalin-cubilin interaction due to decreased cubilin expression may 
change megalin’s binding capacity. As RBP is only reported to bind to megalin, an increase in 
megalin binding capacity could result in increased RBP uptake.  
It is unlikely that the proposed change in megalin binding capacity with decreased cubilin 
expression would also explain the observed increased DBP uptake in LLC-PK1 cells. DBP binds 
to both megalin and cubilin receptors with reportedly similar affinities [128], making it difficult to 
believe a decrease in cubilin would increase uptake. Additionally, the size and secondary protein 
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structure of DBP is very similar to albumin, which did not change in uptake with 1,25(OH)2D 
treatment. To further complicate matters, the increase in DBP with different doses of 1,25(OH)2D 
appeared to be biphasic, suggesting more than one type of interaction. Other receptors for DBP 
are not reported, implying the biphasic nature of its uptake is dependent on megalin/cubilin 
receptors or changes in fluid phase uptake in PT cells. However, it is unlikely that changes in fluid 
phase uptake would selectively increase protein uptake as it is nonspecific in nature. More 
experiments using a wider range of 1,25(OH)2D concentrations are needed to determine any dose 
dependent effects on DBP uptake and to better characterize possible differences between DBP and 
albumin uptake.  
While further studies are needed to understand the exact mechanism of 1,25(OH)2D-related 
effects on PT cell protein endocytosis, we have found differential uptake of specific proteins by 
two PT cell lines with changes in 1,25(OH)2D supplementation. Interestingly, the two vitamin 
carriers tested, DBP and RBP, had increased uptake with 1,25(OH)2D supplementation, suggesting 
a role for active vitamin D signaling in vitamin reabsorption by the PT. An increased uptake of 
DBP with 1,25(OH)2D signaling could indicate an added effort for internalization and degradation 
of excess vitamin D as CYP24A1 expression is also amplified. However, it is difficult to understand 
the clinical significance of observed effects on endocytosis reported here as 1,25(OH)2D 
concentrations used, while common in cell culture experimentation, are supraphysiologic in 
humans and measured effect sizes were rather small. Nevertheless, we report the first evidence of 
changes in endocytosis with varying 1,25(OH)2D levels, which may indicate PT cell protein 
reabsorption is connected to vitamin D status.   
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5.4 Future Directions 
In order to connect the changes in cubilin expression with direct 1,25(OH)2D-VDR 
regulation, in silico analysis of the CUBN gene promoter region in the Sus scrofa genome is needed 
to identify possible VDRE regions. In addition to confirming transcriptional regulation by 
1,25(OH)2D, this information may provide sequence information that could help identify other 
VDREs within the porcine genome and possibly other species. 
We hypothesize that decreased cubilin expression is linked to increased RBP uptake in 
LLC-PK1 cells. To directly test this, we plan to conduct experiments using siRNA knockdown of 
cubilin in PT cells without alteration of 1,25(OH)2D supplementation. Increased RBP uptake with 
specific cubilin knockdown would suggest effects observed with 1,25(OH)2D treatment were 
specific to the downregulation of cubilin expression. However, if no increase in RBP uptake occurs 
with cubilin knockdown 1,25(OH)2D may be causing alternative changes to the endocytic pathway 
to change in RBP uptake. 
We would also like to assess any differences in surface expression of both megalin and 
cubilin after 1,25(OH)2D treatment as this may have an impact on endocytosis. To do this, we will 
biotinylate the apical surface of cells before lysis and protein collection. We can then selectively 
pool surface proteins using streptavidin pull down. Western blotting of this surface pool for 
megalin and cubilin expression could then provide an assessment of surface-specific megalin and 
cubilin. This data could also be confirmed using immunofluorescence analysis of megalin/cubilin 
localization in cells. While we have previously used this method to assess megalin expression in 
OK cells (data not published), its use in LLC-PK1 cells will be difficult as expression of each 
receptor is lower. However, we are currently optimizing an enzyme-linked immunosorbent assay 
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(ELISA) protocol to assess megalin/cubilin expression, which may have the added sensitivity 
needed to probe LLC-PK1 cells. 
Because LLC-PK1 cells reportedly metabolize vitamin D in the same manner as humans it 
is likely 1,25(OH)2D signaling effects on endocytic uptake would also be similar. However, as 
there may be notable differences between species in 1,25(OH)2D-VDR regulation of megalin and 
cubilin expression and endocytosis, it would be advantageous to replicate our studies in human PT 
cells to confirm similar changes in protein uptake. This will likely be difficult as current human 
PT cell lines as well as primary cell cultures generally have poor endocytic capacity. Thus, 
additional efforts will likely be necessary to improve the sensitivity of our assay to allow for 
differential measurement. This could involve measurement of radiolabeled, rather than 
fluorescently-tagged, protein uptake. Additionally, biochemical analyses, such as western blotting 
or ELISA, of protein lysate could provide more sensitive measurement compared to 
spectrofluorimetry. 
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6.0 Conclusions 
As kidney disease becomes an increasing concern for SCD patients, understanding the 
pathophysiology and progression of disease is critical to better develop targeted treatments. 
Tubular proteinuria commonly occurs early in SCD patients before the onset of many other clinical 
symptoms of renal dysfunction, suggesting the PT as an excellent target for therapeutic 
intervention. Over the course of my studies, I have worked to characterize how PT function is 
affected by exposure to the increased cell-free Hb levels expected to be present in SCD. Through 
measurement of endocytic uptake of fluorescently-labeled proteins, I found that Hb selectively 
competes for megalin/cubilin receptor binding and internalization in PT cells. This binding 
competition may be selective based on protein secondary structure as Hb dramatically inhibited 
highly alpha helical proteins albumin and DBP, but only marginally inhibited RBP, which is 
comprised primarily of β-sheets. Inhibition of normally filtered protein uptake by increased 
concentrations of Hb may be the primary cause of tubular proteinuria.  
Because the PT is the primary site of vitamin D activation, megalin/cubilin receptor-
mediated endocytosis of DBP is critical for vitamin D retention and homeostasis. In these studies, 
I demonstrated that DBP is dramatically inhibited by Hb not just at high concentrations expected 
during hemolytic crisis but also at expected chronic levels. This suggests SCD patients could be 
losing DBP-associated vitamin D in their urine regularly. The urinary loss of vitamin D could 
contribute to vitamin D deficiency in patients, especially if these patients aren’t properly 
supplemented. In addition to inhibition of vitamin D internalization, I found that prolonged Hb 
exposure caused alteration of expression of vitamin D activating enzyme CYP27B1 in PT cells, 
suggesting vitamin D metabolism may be affected by Hb exposure. Changes to CYP27B1 could 
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be driven by increased oxidative stress, which have been reported previously to affect hydroxylase 
expression and activity [175, 176]. In fact, I have found evidence of increased oxidative stress, 
through measurement of decreased aconitase activity and increased cytoprotective HO-1 
expression, in my PT culture model. However, further studies are needed to understand the effect 
of prolonged Hb exposure on hydroxylase activity in order to assess any remarkable change in 
vitamin D metabolism. I am currently generating samples from both cell culture and Townes SCD 
mouse models to profile vitamin D metabolites and describe any alteration in metabolism. 
Changes in PT vitamin D metabolism in the context of SCD could affect levels of active 
1,25(OH)2D. Because 1,25(OH)2D-VDR signaling in the PT is reported to alter expression of 
megalin and cubilin, I looked to understand any effects it may have on endocytic uptake. I found 
that changes in 1,25(OH)2D availability led to differential changes in cubilin expression as well as 
increased DBP and RBP uptake. Although observed increases in endocytic uptake were rather 
small with 1,25(OH)2D treatment, this may indicate SCD patients could have further difficulty in 
protein reabsorption if deficient in 1,25(OH)2D levels. This could further contribute to the 
progression of vitamin deficiency observed in patients. 
Although my analysis was limited to the cellular level, I have provided evidence that may 
link increased cell-free Hb exposure to the development of tubular proteinuria and vitamin D 
deficiency in SCD patients. As many of the effects of Hb on PT cell function reported here rely on 
endocytic uptake of Hb, there may be therapeutic potential in compounds that could selectively 
inhibit Hb’s interaction with megalin and cubilin receptors. Selective inhibition of Hb uptake could 
allow PT cell reabsorption of normally filtered proteins to prevent tubular proteinuria and reduce 
Hb-induced toxicity to preserve PT function. Additionally, the prevention of Hb internalization at 
the expense of DBP could have therapeutic value in preserving vitamin D reclamation and 
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activation by the PT. Although it may be difficult to selectively inhibit Hb uptake by cells due to 
likely similarity in binding domains with proteins like albumin and DBP, compounds that could 
inhibit all endocytosis may still be useful to preserve PT cell health during hemolytic crisis when 
high concentrations of Hb are entering the tubule lumen.
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Appendix A. Introductory Tables and Figures 
Table 2. Reported forms of sickle cell disease. 
Genotype β-globin mutation 
Severe disease 
HbS/S p.6Glu>Val/p.6Glu>Val 
HbS/β⁰ thalassaemia p.6Glu>Val/various 
HbS/β+ thalassaemia p.6Glu>Val/various 
HbS/O Arab p.6Glu>Val/p.121Glu>Lys 
HbS/D Punjab p.6Glu>Val/p.121Glu>Gln 
HbS/C Harlem p.6Glu>Val/p.6Glu>Val, p.73Asp>Asn 
HbC/S Antilles p.Glu>Lys/p.6Glu<Val, p.23Val>Ile 
HbS/Quebec-CHORI p.6Glu>Val/p.87Thr>Ile 
Moderate disease 
HbS/C p.6Glu>Val/p.6Glu>Lys 
HbS/β⁺ thalassaemia p.6Glu>Val/various 
HbA/S Oman unchanged/p.6Glu>Val, β121Glu>Lys 
Mild disease 
HbS/β⁺⁺ thalassaemia p.6Glu>Val/various 
HbS/E p.6Glu>Val/p.26Glu>Lys 
HbA/S Jamaica Plain unchanged/p.6Glu>Val, p.68Leu/Phe 
Very mild disease 
HbS/HPFH p.6Glu>Val/various 
HbS/other variants p.6Glu>Val/various 
 
All genotypes known to cause SCD include at least one copy of the HbS variant. Some variants listed include two mutations to 
one allele and are denoted by a comma between mutations listed. β-thalassaemia alleles are variable and are characterized by 
their resulting reduction in Hb expression (β⁰ = complete loss of expression, β+ = residual expression remaining (~10%), β++ = 
mild reduction in expression) [25]. HPFH = hereditary persistence of fetal haemoglobin, is caused by large deletions within the 
β-globin gene cluster [193]. 
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Table 3. Physiologic concentrations and binding affinities of proteins relevant to this study. 
Protein 
Size 
(kDa) 
Glomerular 
sieving coefficient 
(GSC) 
Megalin 
binding 
affinity (Kd) 
Cubilin 
binding 
affinity (Kd) Serum Level 
Tubular level 
(estimated) 
Albumin 65.5 6.2 x 10-4 Not reported 0.63µM 4.5g/dL (687µM) 2.8mg/dL (427nM) 
Hemoglobin (Hb) 
    Normal 
    SCD chronic 
    SCD hemolytic crisis 
16.125 0.03 1.7µM 4.1µM  
3mg/dl (1.9µM) 
~30mg/dl (20µM) 
≤1g/dl (620µM) 
 
90µg/dl (55.8nM) 
~900µg/dl (558nM) 
≤ 30mg/dl (20µM) 
Retinol-binding protein 
(RBP) 21 0.38 12.0-36.2µM Not reported 580µg/dL (276.2nM) 220µg/dL (105nM) 
Vitamin D-binding 
protein (DBP) 51.3 1.6 x 10
-3 120nM 110nM 40mg/dL (7.8µM) 64ng/dL (12.5nM) 
 
Serum levels of albumin, RBP, and DBP were reported in Norden [194].The glomerular sieving coefficient (GSC) found in rats by Tojo [195] was used to estimate tubular 
levels of albumin. We believe this is a more accurate estimate than the human albumin sieving coefficient calculated by Norden based on measurements of urinary albumin 
in Dent disease patients [194] because that study assumed no albumin is reabsorbed by the PT. The difference between reported albumin GSCs found in Tojo and Norden 
was applied to approximate the GSC and tubular levels of DBP as it is comparable to albumin in size and should be filtered similarly. Because of the large difference in size 
of RBP from albumin, the GSC found in Norden was used to estimate tubular levels. Hb tubular levels were estimated based on GSC found in Monke [59] and serum 
concentrations reported in Naumann [158]. Binding affinities for albumin [182], Hb [60], RBP [183], and DBP [128] were previously reported in citations listed. Albumin 
has been shown to bind to megalin [98], but its binding affinity has not been reported. Albumin’s affinity to megalin is thought to be comparable to its affinity to cubilin. 
Ability of RBP to bind to cubilin has not been tested. 
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Table 4. Common complications of sickle cell disease. 
Clinical complication Brief description 
Cardiothoracic system 
Cardiomegaly Enlargement of the heart 
Chronic restrictive lung 
disease 
Restricted lung expansion, resulting in decreased lung volume and 
inadequate oxygenation 
Pulmonary hypertension High blood pressure in pulmonary arteries 
Diastolic heart failure Left ventricle inability to fill during diastolic phase, reducing the amount of 
blood pumped by the heart  
Acute chest syndrome Vaso-occlusive crisis of the pulmonary vasculature 
Dysrhythmias Abnormal rhythm of the heart 
Nervous system 
Hemorrhagic stroke Arterial bleeding into the brain 
Venous sinus thrombosis Blood clotting within the dural venous sinuses of the brain 
Acute ischemic stroke Sudden loss of blood flow to the brain 
Silent cerebral infarction Abnormal magnetic resonance imaging (MRI) of the brain without history or 
physical findings of a stroke 
Proliferative retinopathy Development of new, fragile blood vessels in the retina 
Chronic pain Any pain lasting more than 12 weeks 
Orbital infarction Ischemia of all intraorbital and intraocular structures due to occlusion of the 
ophthalmic artery and its branches 
Cognitive impairment Trouble remembering, learning, concentrating, and/or making decisions 
Immune system 
Leukocytosis Abnormally high white blood cell count 
Septicemia Bacterial infection of the blood 
Splenic sequestration Trapped blood in the spleen; can lead to enlargement/damage to the spleen 
Functional hyposplenism Reduced splenic function characterized by defective immune response 
against infection 
Anemia Red blood cell deficiency 
Hemolysis Rupture of red blood cells 
Musculoskeletal system 
Avascular necrosis Death of bone tissue due to inadequate blood flow  
Skin ulceration Open sores on the skin, commonly found on legs 
Urogenital System 
Papillary necrosis Tissue death in renal papillae 
Proteinuria Excretion of protein in the urine; can manifest as tubular proteinuria or frank 
proteinuria 
Renal failure Loss of kidney function 
Hematuria Presence of blood in the urine 
Hyposthenuria Secretion of low specific gravity urine due to concentrating defect 
Priapism Persistent/painful erection of the penis 
Gastrointestinal system 
Cholelithiasis Gallstone formation 
Ischemic cholangiopathy Bile duct damage caused by inadequate blood flow 
Hepatopathy Liver damage caused by venous congestion 
Mesenteric vaso-
occlusion/ischemia 
Arterial blockage/ischemia of the intestine, commonly the small intestine 
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Table 5. Megalin and cubilin ligands that are filtered through the glomerular barrier. 
Protein Megalin ligand Cubilin ligand 
Vitamin carrier proteins 
Vitamin D–binding protein Yes Yes 
Folate–binding protein Yes 
 
Retinol–binding protein Yes 
 
Transcobalamin, Transcobamalin II Yes 
 
Intrinsic factor 
 
Yes 
Other carrier proteins 
Albumin Yes Yes 
Hemoglobin Yes Yes 
Myoglobin Yes Yes 
Lactoferrin Yes 
 
Liver-type fatty acid–binding protein Yes 
 
Metallothionein Yes 
 
Neutrophil gelatinase-associated lipocalin Yes 
 
Odorant–binding protein Yes 
 
Selenoprotein P Yes 
 
Sex hormone–binding globulin Yes 
 
Transthyretin Yes 
 
Transferrin 
 
Yes 
Lipoproteins 
Apolipoprotein B Yes 
 
Apolipoprotein E Yes 
 
Apolipoprotein J/clusterin Yes 
 
Apolipoprotein H Yes 
 
Apolipoprotein M Yes 
 
Apolipoprotein A-I 
 
Yes 
High-density lipoprotein 
 
Yes 
Hormones and signaling proteins 
Angiotensin II Yes 
 
Bone morphogenic protein 4 Yes 
 
Connective tissue growth factor Yes 
 
Epidermal growth factor Yes 
 
Insulin Yes 
 
Insulin-like growth factor Yes 
 
Leptin Yes 
 
Parathyroid hormone Yes 
 
Prolactin Yes 
 
Sonic hedgehog protein Yes 
 
Survivin Yes 
 
Thyroglobulin Yes 
 
Fibroblast growth factor 
 
Yes 
83 
Enzymes and enzyme inhibitors 
Recombinant activated factor VIIa Yes Yes 
α-amylase Yes 
 
α-galactosidase A Yes 
 
Cathepsin B Yes 
 
Cystatin C Yes 
 
Lysozyme Yes 
 
Plasminogen Yes 
 
Plasminogen activator inhibitor type I Yes 
 
Tissue plasminogen activator Yes 
 
Urokinase Yes 
 
Lipoprotein lipase Yes 
 
Immune- and stress-related proteins 
Immunoglobulin light chains Yes Yes 
α1-microglobulin Yes Yes 
β2-microglobulin, Pancreatitis-associated protein Yes 
 
Clara cell secretory protein 
 
Yes 
Drugs and toxins 
Aminoglycosides Yes Yes 
Aprotinin Yes 
 
Colistin Yes 
 
Gentamicin Yes 
 
Polymyxin B Yes 
 
Trichosanthin Yes 
 
Others 
Ca2+ Yes Yes 
Receptor-associated protein Yes Yes 
Coagulation factor VII Yes Yes 
Coagulation factor VIII Yes 
 
Cytochrome C Yes 
 
Seminal vesicle secretory protein II Yes 
 
Advanced glycation end products Yes 
 
Table 5 Continued 
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Figure 18. Vitamin D activation in the body. 
Prohormone vitamin D enters the body system in one of two ways: (1) UV irradiation and thermal rearrangement of 
7-dehydrocholesterol in the skin or (2) dietary intake. This prohormone vitamin D is then transported to the liver 
where enzymes CYP2R1 and (possibly) CYP27A1 convert it to 25-dihydroxyvitamin D [25(OH)D], an inactive form 
of vitamin D primed for activation. Once primed in the liver, 25(OH)D is transported to the kidney PT where it is 
converted to its active form 1,25(OH)2D by CYP27B1. Note: Structures of vitamin D3 (cholecalciferol) form are 
shown here. Plant based vitamin D2 (ergocalciferol) would enter the system only through dietary uptake but otherwise 
would be processed identically to vitamin D3. 
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Figure 19. Effects of vitamin D signaling on immune cell maturation and corresponding cytokine expression. 
Active vitamin D [1,25(OH)2D] regulates immune cell maturation and cytokine expression to reduce inflammation 
overall. 1,25(OH)2D signaling promotes monocyte maturation into macrophages over dendritic cells and shifts T cell 
maturation toward Th2 and Treg cells. Correspondingly, this shift in maturation alters production key cytokines with 
decreased pro-inflammatory (red) and increased anti-inflammatory (green) cytokine expression. Abbreviations: Th1, 
T helper cell type 1; Th2,  T helper cell type 2; Th17, T helper cell type 17; Treg, regulatory T cell; IFN, interferon; 
IL, interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor. 
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Appendix B. Supplementary Data 
 
Figure 20. Hb and albumin compete for proximal tubule cell uptake. 
OK cells grown in a 96-well plate format were incubated with 0.6 µM Alexa Fluor 647-albumin and a range of Alexa 
Fluor-488 Hb concentrations (0-20 µM) for 2 h at 37°C. Cells were then solubilized and cell-associated albumin and 
Hb fluorescence were quantified by spectrofluorimetry. Data (mean ± SD) from three experiments performed in 
sextuplicate are shown. Graphed uptake values were normalized by dividing each point by their respective 
experimental mean. *p≤0.05, ****p≤0.0001 by two-way ANOVA Dunnett’s multiple comparisons. 
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Figure 21.Chronic metHb, but not oxyHb, exposure decreases aconitase activity in LLC-PK1 cells. 
Filter-grown LLC-PK1 cells were incubated with metHb (A) or oxyHb (B) for 24-72 h at concentrations indicated. 
Cells were then washed, lysed, and equal lysate volumes were incubated with aconitase substrate for 1 h. Colorimetric 
measurement of isocitrate production was used to quantify aconitase activity and normalized to total protein. Data 
(mean ± SD and individual points) from three experiments are plotted. Graphed values were normalized by dividing 
each point by their respective experimental mean. These results are similar to experiments done is OK cells (Fig. 13). 
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Figure 22. CYP24A1 mRNA expression is upregulated by 1,25(OH)2D in proximal tubule cells. 
Filter-grown LLC-PK1 (A) and OK (B) cells were incubated with 1,25(OH)2D for 24 h at concentrations indicated. 
Cells were then washed, lysed, and total RNA was collected. Expressional changes of CYP24A1 transcript were 
quantified by qPCR and normalized to ACTB transcript levels. Relative fold change (RFC) in treatment conditions 
compared to an untreated control (not shown) from 2-3 experiments are plotted (mean ± SD and individual points).   
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Appendix C. List of Abbreviations 
1,25(OH)2D – 1,25-dihydroxyvitamin D; calcitriol 
1,24,25(OH)3D – 1,24,25-trihydroxyvitamin D 
24,25(OH)2D – 24,25-dihydroxyvitamin D; dihydroxycholecalciferol 
25(OH)D – 25-hydroxyvitamin D; calcifediol 
2,3-DPG – 2,3-diphosphoglycerate 
ACE – angiotensin converting enzyme 
ARB – angiotensin receptor type II blocker 
BSA – bovine serum albumin 
CKD – chronic kidney disease 
CO2 – carbon dioxide 
CUB – complement C1r/C1s, Uegf, Bmp1 
DBP – vitamin D binding protein 
EGF – epidermal growth factor 
ESRD – end-stage renal failure 
ETA – endothelin type A receptor 
FcRN – MHC-related Fc receptor for IgG  
Fe2+ – iron, ferrous state 
Fe3+ – iron, ferric state 
GSC – glomerular sieving coefficient 
H+ – hydrogen atom  
Hb – hemoglobin  
HbA – hemoglobin A 
HBB –hemoglobin β-globin subunit gene 
HbC – hemoglobin C 
HbF – hemoglobin F 
HbS – hemoglobin S 
HO-1 – heme oxygenase-1 
Hpt – haptoglobin 
IFN-γ – interferon gamma 
IL-1β – interleukin 1 beta 
IL-10 – interleukin 10 
IL-12 – interleukin 12 
IL-17 – interleukin 17 
IL-2 – interleukin 2 
IL-21 – interleukin 21 
IL-4 – interleukin 4 
IL-6 – interleukin 6 
LDLR – low-density lipoprotein receptor 
LMW – low molecular weight 
L-NAME – L-NG-nitroarginine methyl ester 
O2 – oxygen molecule 
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OK – opossum kidney 
oxyHb – oxyhemoglobin 
MDCK – Madin-Darby canine kidney 
metHb – methemoglobin 
CNmetHb – cyanmethemoglobin  
NO – nitric oxide 
NOS – nitric oxide synthase 
NSAIDs – nonsteroidal anti-inflammatory drugs 
PT – proximal tubule 
RAP – receptor-associated protein 
RBCs – red blood cells 
RBP – retinol binding protein  
ROS – reactive oxygen species 
SCD – sickle cell disease 
SCN – sickle cell nephropathy 
TGF-β – transforming growth factor beta 
Th1 – T helper cell type 1  
Th17 – T helper cell type 17 
Th2 – T helper cell type 2 
TNF-α – tumor necrosis factor alpha 
Treg – regulatory t cell 
VDR – vitamin D receptor 
VDRE – vitamin D response element 
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